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pAs in past years, this Highlights article takes the place of the
Editor’s Page, and was assembled by the associate editors
based upon the papers that they perceived had or would
have the greatest impact upon cardiology. Space constraints
result in omitting many excellent papers, and we apologize
in advance to those authors.
Transcatheter aortic valve replacement. Perhaps the
most exciting advance this past year involved the develop-
ment, validation, and approval of transcatheter aortic valve
replacement (TAVR) for aortic stenosis.
A weighted meta-analysis of 16 studies including 3,519
patients determined the rates of major outcomes after
TAVR using Valve Academic Research Consortium
(VARC) definitions and demonstrated a high adverse event
rate at present. Device success was 92.1%, all-cause 30-day
mortality 7.8%, myocardial infarction (MI) 1.1%, acute
kidney injury stage II/III 7.5%, life-threatening bleeding
15.6%, major vascular complications 11.9%, major stroke
3.2%, and new permanent pacemaker implantation 13.9%.
Medtronic CoreValve (Minneapolis, Minnesota) prosthesis
use was associated with a significant higher rate of new
permanent pacemaker implantation compared with the
Edwards Lifesciences prosthesis (28.9% vs. 4.9%, p 
0.0001). The 30-day safety composite endpoint rate was
32.7%, and the 1-year total mortality rate was 22.1% (1).
The severity of periprosthetic aortic regurgitation
(periAR) was prospectively evaluated in 146 patients treated
with the Medtronic CoreValve prosthesis by echo, angiog-
raphy, and measurement of the aortic regurgitation (AR)
index  [(diastolic blood pressure  left ventricular end-
iastolic pressure)/systolic blood pressure  100] (2). The
R index decreased stepwise from 31.7 with no periAR to
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vailable online on the JACC home page.8.0 with mild, 19.6 with moderate, and 7.6 with severe
eriAR (p  0.001). Patients with an AR index 25 had a
ignificantly increased 1-year mortality risk. The AR index
rovided additional prognostic information beyond the
chocardiographically assessed severity of periAR and inde-
endently predicted 1-year mortality (hazard ratio [HR]:
.9; p  0.009).
A total of 202 consecutive patients with no baseline
entricular conduction disturbances who underwent
alloon-expandable valve TAVR were examined to assess
ew left bundle branch block (LBBB). New-onset LBBB
as observed in 30% of patients after TAVR, and had
esolved in 37.7% and 57.3% at hospital discharge and 6- to
2-month follow-up, respectively. Baseline QRS duration
nd ventricular depth of the prosthesis were independent
redictors of persistent LBBB, which was associated with
ecreased ejection fraction at hospital discharge and poorer
unctional status at 1 year. Patients with persistent LBBB
nd no pacemaker at hospital discharge had more syncope
16.0% vs. 0.7%; p  0.001) and greater permanent pace-
aker need (20.0% vs. 0.7%; p  0.001), but not global
ortality. Up to 30% of patients with no prior conduction
isturbances developed new LBBB following TAVR with a
alloon expandable valve, although it was transient in more
han one-third (3).
A total of 358 patients underwent transapical TAVR
ith balloon-expandable prostheses using a modified pro-
edural strategy of precise prosthesis positioning and imme-
iate additional intraprocedural treatment with the goal to
liminate paravalvular leakage (4). Balloon redilation of the
ranscatheter valve was performed in 18 patients (5%), and
dditional second valves were implanted in 13 (4%). At the
nd of the procedure, 52% had no paravalvular or transval-
ular regurgitation. Leakage was trace in 25%, mild in 23%,
nd moderate in 6% of patients. Cumulative survival was
ot dependent on post-procedural regurgitation rate.
Consecutive patients (n  137) undergoing transfemoral
AVR from 2009 to 2010 were evaluated at baseline,
ost-procedure, and at 30 days (5). Smaller sheaths, rigor-
us angiographic and computed tomographic screening and
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niques were increasingly used over this period. Over the 2
years, major vascular complications decreased from 8% to
1% (p 0.06), minor vascular complications decreased from
24% to 8% (p  0.01), major bleeds fell from 14% to 1%
(p  0.01), and unplanned surgery decreased from 28% to
2% (p  0.01). A smaller artery than sheath diameter,
moderate or severe calcification, and peripheral vascular disease
were associated with higher vascular complication rates.
The outcomes of patients with mitral regurgitation (MR)
were evaluated after TAVR (6). Moderate or severe MR in
patients undergoing TAVR is associated with a higher early,
but not late, mortality rate. One year after TAVR, moderate
MR had improved in 58% of patients, remained moderate
in 17%, and worsened to severe in 1%, and 24% of patients
had died. Severe MR had improved in 49% and remained
severe in 16%, and 35% of patients had died. Improvement
was more likely in patients with high transaortic gradients,
with functional MR, without pulmonary hypertension and
without atrial fibrillation. Two studies from Europe and
Canada reported that female sex is associated with better
short- and long-term survival after TAVR (7,8).
The most definitive studies regarding TAVR in high-risk
or inoperable patients were the PARTNER trials (Place-
ment of AoRTic TraNscathetER Valve Trial) (9). In a
substudy of PARTNER, Reynolds et al. (10) reported the
health-related quality of life after TAVR in high-risk
patients with severe aortic stenosis (AS). The primary
outcome, the Kansas City Cardiomyopathy Questionnaire
summary score, improved more rapidly with TAVR but was
similar for the 2 groups at 6 and 12 months. However, there
was significant interaction between the benefit of TAVR
and access site; patients undergoing transfemoral TAVR
demonstrated significant improvement in health status. In
another substudy, Genereux et al. (11) report on vascular
complications after TAVR. They observed that 15.3% of
patients had major and 11.9% minor vascular complications
within 30 days of the procedure, most frequently vascular
dissection, perforation, and access site hematoma. Major
complications were associated with a significantly higher
30-day rate of major bleeding, transfusions, renal failure
requiring dialysis, and a higher 30-day and 1-year mortality.
The only identifiable independent predictor of complica-
tions was female sex.
In an attempt to standardize definitions and endpoints of
clinical studies involving TAVR, the VARC updated their
second consensus document in JACC (12). The VARC
documents have provided the mainstay of standardization
for designing and reporting clinical trials of TAVR in
patients with critical AS.
Which measurement to use for aortic annular sizing
before transcatheter aortic valve implantation remains un-
clear. Using 4-dimensional analysis of 256-slice computed
tomography (CT), it was shown that the aortic annulus
assumes a more round shape in systole, which increases the
cross-sectional area without changing the perimeter inpatients with calcified aortic valves. Accordingly, the annu-
lus perimeter may be the preferred measurement for sizing
in transcatheter aortic valve implantation (13).
Several studies have examined the optimal imaging tech-
nique to measure aortic annulus size so as to limit the risk of
aortic regurgitation. Jilaihawi et al. (14) compared com-
puted tomography to 2-dimensional echocardiography and
found the computed tomography superior in sizing the
aortic annulus for TAVR procedures, and reduced the
occurrence of aortic regurgitation worse than mild from
21.9% to 7.5% compared with 2-dimensional echo. Willson
et al. (15) found similar results despite the use of
3-dimensional echocardiography; the difference between the
size of the valve and of the aortic annulus by computed
tomography was predictive of the presence of aortic regur-
gitation. These 2 papers together clearly establish the
superiority of computed tomography in assessing aortic
annulus and preventing aortic regurgitation in TAVR.
Finally, the incidence and predictive factors for atrial fibril-
lation following TAVR were reported by Amat-Santos et al.
(16). They found that new-onset atrial fibrillation occurred
in 31.9% of patients at a median of 48 h after the procedure,
and were predicted by a left atrial size and the transapical
approach. At 30 days, atrial fibrillation was associated with
a higher rate of stroke and systemic embolus (13.6 vs. 3.2)
with no difference in mortality rate.
STENT trials. The TWENTE trial (The Real-World
Endeavor Resolute Versus XIENCE V Drug-Eluting
SteNt Study: Head-to-head Comparison of Clinical Out-
come After Implantation of Second Generation Drug-
eluting Stents in a Real World Scenario) compared the
safety and efficacy of Resolute (Medtronic) zotarolimus-
eluting stents (ZES) (n  699) with Xience V (Boston
Scientific, Natick, Massachusetts) everolimus-eluting stents
(EES) (n  694) at 1 year (9). Acute coronary syndromes
were present in 52% and “off-label” features in 77% of
patients. In ZES and EES, target vessel baseline occurred in
8.2% and 8.1%, respectively (absolute risk-difference 0.1%;
p-noninferiority  0.001). Resolute ZES were noninferior
to Xience V EES in treating “real-world” patients with a
vast majority of complex lesions and “off-label” indications
for drug-eluting stents (17).
The SORT OUT IV (Scandinavian Organization for
Randomized Trials With Clinical Outcome IV) trial com-
pared 1,390 patients treated with EES or sirolimus-eluting
stents (SES) (18). At 2 years, the composite primary
endpoint occurred in 8.3% in the EES group and in 8.7% in
the SES group (HR: 0.94). Rate of definite stent thrombo-
sis was lower in the EES group (0.2% vs. 0.9%) EES was
noninferior to the SES for both patient-related and stent-
related clinical outcomes.
Patients with in-stent restenosis of DES were random-
ized according to lesion length to compare outcomes of SES
versus cutting balloon angioplasty for focal type (10 mm,
n  96) and SES versus EES for diffuse type (10 mm,
n  66) (19). In focal lesions, in-segment late loss was
t
f
D
c
a
t
l
s
s
i
s
S
P
r
A
e
w
(
r
S
c
1
S
t
P
S
p
(
h
h
f
6
(
o
P
S
(
359JACC Vol. 61, No. 3, 2013 DeMaria et al.
January 22, 2013:357–85 Highlights from JACC 2012significantly higher in the cutting balloon group than in the
SES group (0.25 mm vs. 0.06 mm). In diffuse in-stent
restenosis, in-segment late loss (0.11 mm vs. 0.00 mm),
in-segment restenosis rate (5.0% vs. 14.3%), and the com-
posite of death, MI, or target vessel restenosis [TVR] (9.6%
vs. 8.8%) did not differ between SES and EES. For focal
DES restenosis, repeat SES implantation is more effective
than cutting balloon angioplasty. For diffuse DES resteno-
sis, implantation of SES or EES is comparably effective.
Patients (n  2,095) treated with placlitaxel-coated
balloons (PCB) were evaluated for clinically driven target
lesion revascularization (TLR) rate at 9 months in 75
centers (20). The TLR rate was 5.2% after 9.4 months, and
definite vessel thrombosis occurred in 0.1%. PCB angio-
plasty was more effective in bare-metal stent (BMS) reste-
nosis compared with DES restenosis, with no difference
regarding the type of DES. PCB angioplasty in an all-
comers, prospective, multicenter registry was safe, and
confirmed in a large population the low TLR rates seen in
randomized clinical trials.
This PEPCAD DES (Treatment of DES-In-Stent Re-
stenosis With SeQuent Please Paclitaxel Eluting PTCA
Catheter) study (21), was a prospective, single-blind, mul-
ticenter trial that randomly assigned 110 patients to PCB
angioplasty for treatment of DES restenosis compared with
uncoated balloon angioplasty. Treatment with PCB was
superior to balloon angioplasty alone, with a late loss of 0.43
mm versus 1.03 mm (p  0.001). Restenosis rate was
significantly reduced from 58.1% to 17.2% (p  0.001), and
he composite clinical endpoint was significantly reduced
rom 50.0% to 16.7% (p  0.001), respectively. The
EB-AMI (Drug-Eluting Balloon in Acute MI) study (22)
ompared PCB plus BMS versus BMS versus DES for
cute ST-segment elevation MI (STEMI). In contrast to
he aforementioned studies, PCB in STEMI patients fol-
owed by BMS implantation failed to show angiographic
uperiority to BMS only. Angiographic results of DES were
uperior to both BMS and DEB. Moreover, PCB before
mplantation induced more uncovered and malapposed
tent struts than BMS, but fewer than after.
The EVOLVE (A Prospective Randomized Multicenter
ingle-Blind Noninferiority Trial to Assess the Safety and
erformance of the Evolution Everolimus-Eluting Mono-
ail Coronary Stent System for the Treatment of a De Novo
therosclerotic Lesions) study (23) compared the safety and
fficacy of a novel bioabsorbable polymer EES (SYNERGY)
ith that of the durable polymer PROMUS Element EES
n  291) (both stents, Boston Scientific). Patients were
andomly assigned in a 1:1:1 ratio to PROMUS Element,
YNERGY, or SYNERGY half-dose. The 30-day primary
linical endpoint of target lesion failure occurred in 0%,
.1%, and 3.1% of patients in the PROMUS Element,
YNERGY, and SYNERGY half-dose groups, respec-
ively. The 6-month in-stent late loss was 0.15 mm for
ROMUS Element, and noninferior 0.10 mm for
YNERGY, and 0.13 mm for SYNERGY half-dose.A total of 625 patients with acute MI (AMI) were
randomized (2:1) to receive EES or SES in the noninferi-
ority XAMI (Xience V Stent vs. Cypher Stent in Primary
PCI for Acute MI) trial (24). The MACE rate was 4.0% for
EES and 7.7% for SES; the relative risk was 0.52. One-year
cardiac mortality and 1-year incidence of definite and/or
probable stent thrombosis of 1.2% was similar for EES and
SES (p  0.21). In this all-comer, randomized, multicenter
AMI trial, second-generation EES was noninferior to SES,
and superiority for MACE was suggested.
A study assessed percutaneous coronary intervention
(PCI) for unprotected left main coronary artery (ULMCA)
stenosis in routine U.S. clinical practice in 5,627 patients
undergoing ULMCA PCI at 693 centers within the Na-
tional Cardiovascular Data Registry Catheterization Percu-
taneous Coronary Intervention Registry from 2004 to 2008
(25). ULMCA PCI was performed in 4.3% of patients with
ULMCA stenosis. Unadjusted in-hospital mortality rates
ranged from 2.9% for elective cases to 45.1% for emergent/
salvage cases. By 30 months, 57.9% of the elderly ULMCA
PCI population experienced death, MI, or revascularization,
and 42.7% died. Patients receiving DES (versus BMS) had
a lesser 30-month mortality rate, but the composite of major
adverse cardiac events (MACE) was similar.
The etiology of late complications of in-stent restenosis
and stent thrombosis is not well defined. Studies have
reported that one-third of patients with in-stent restenosis
of BMS presented with acute coronary syndromes (ACS),
and both clinical and histological studies of DES have
demonstrated evidence of continuous neointimal growth
during long-term follow-up, which is designated as “late
catch-up” phenomenon. Emerging evidence is presented of
de novo neoatherosclerosis within stents based on histology,
angioscopy, and intravascular images that provide a new
insight for the mechanism of late stent failure. In-stent
neoatherosclerosis is an important substrate for late stent
failure for both BMS and DES, especially in the extended
phase. In light of the rapid progression in DES, early
detection of neoatherosclerosis may be beneficial to improv-
ing long-term outcome of patients with DES implants (26).
Le May et al. (27) evaluated 1,389 consecutive STEMI
atients in a single emergency medical system, of whom 822
59.2%) were directly transported to a primary PCI-capable
ospital and 567 (40.8%) transported to a non–PCI-capable
ospital first. This resulted in shorter door-to-balloon times
or the direct transport to a PCI-capable hospital (median
6 vs. 117 min, p  0.001) and lower 6-month mortality
5.0% vs. 11.5%, p  0.001). This study provides unequiv-
cal support for preferentially transporting MI patients to
CI-capable hospitals.
Mehta et al. (28) compared outcomes in patients with
TEMI (n  1,958) and non–ST-segment elevation ACS
n 5,063) from the large multicenter randomized RIVAL
(Radial vs Femoral Access for Coronary Intervention) trial
comparing the femoral and radial access site approaches
during PCI. Radial access reduced the primary endpoint,
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0.026), and the secondary endpoint (30-day death, MI,
stroke) (2.7% vs. 4.6%, p  0.031) and mortality (1.3% vs.
3.2%, p  0.006) compared with the femoral approach in
STEMI but not non-STEMI patients. Similarly, Romag-
noli et al. (29) randomized 1,001 patients with ST-segment
elevation acute coronary syndrome in the RIFLE (Radial
versus Femoral Randomized Investigation in ST Elevation
Acute Coronary Syndrome) trial to the radial versus femoral
approach. The primary endpoint (30-day cardiac death,
stroke, MI, target lesion revascularization, and bleeding)
was lower with the radial approach (13.6% vs. 21.0%, p 
0.003) as was cardiac mortality (5.2% vs. 9.2%, p  0.020)
and bleeding (7.8% vs. 12.2%, p  0.026). An accompany-
ing editorial by Bertrand and Patel (30) points out that
although mortality appears to be reduced by the radial
approach for STEMI patients in both of these trials, further
understanding of the mechanism by which this might be
occurring is required.
Optical coherence tomography. The International Work-
ing Group for Intravascular Optical Coherence Tomogra-
phy (IWG-IVOCT) Standardization and Validation, com-
prising more than 260 academic and industry members from
Asia, Europe, and the United States, presented a review on
the current state of the art and its recommendations on key
areas within the IVOCT field as a consensus document
(31). This document may be broadly used as a standard
reference regarding the current state of the IVOCT imaging
modality, intended for researchers and clinicians who use
IVOCT and analyze IVOCT data.
Concomitant optical coherence tomography (OCT) and
intravascular ultrasound (IVUS) area measurements were
performed in a subgroup of patients to compare the diag-
nostic efficiency of both techniques to fractional flow reserve
(FFR) (32). An overall moderate diagnostic efficiency of
OCT was found (area under the curve [AUC]: 0.74; with
sensitivity/specificity of 82%/63% associated with an opti-
mal cutoff value of 1.95 mm2). Comparison of the results in
patients with simultaneous IVUS and OCT imaging re-
vealed no significant differences in the diagnostic efficiency.
In the subgroup of small vessels (reference diameter 3
mm), OCT showed a significantly better diagnostic effi-
ciency (AUC: 0.77) than IVUS (AUC: 0.63) to identify
functionally significant stenoses (p  0.04). In conclusion,
OCT has a moderate diagnostic efficiency in identifying
hemodynamically severe coronary stenoses. Although OCT
seems slightly superior to IVUS for this purpose (particu-
larly in vessels 3 mm), its low specificity precludes its use
s a substitute of FFR for functional stenosis assessment.
A study assessed the diagnostic value of OCT in 17
atients with suspected spontaneous coronary artery dissec-
ion (SCAD). OCT ruled out the diagnosis of SCAD in 6
atients. In 11 patients, OCT confirmed the presence of
CAD as a double-lumen or intramural hematoma image;
nly 3 patients presented an intimal “flap” on angiography.
CT readily identified the intimal rupture site, the thick- oess and length of the intimomedial membrane, the area of
he true and false lumen, and the associated intramural
ematoma and thrombi in the true or false lumen (33).
nstantaneous wave-free ratio. Assessment of stenosis
everity with FFR requires that coronary resistance be stable
nd minimized, conventionally by administration of agents
uch as adenosine. A new study presented an adenosine-
ndependent, pressure-derived index of coronary stenosis
everity determined when resistance is naturally minimized
t rest (34). In part 1 (39 stenoses), intracoronary pressure
nd flow velocity were measured both at baseline and
denosine distal to the stenosis; in part 2 (118 stenoses),
ntracoronary pressure alone was measured. Wave-intensity
nalysis identified a wave-free period in which intracoronary
esistance at rest is similar in variability and magnitude to
hose during FFR. The resting distal-to-proximal pressure
atio during this period, the instantaneous wave-free ratio,
orrelated closely with FFR (r  0.9, p  0.001) with
xcellent diagnostic efficiency (receiver-operating character-
stic area under the curve of 93%, at FFR 0.8) and
pecificity, sensitivity, and negative and positive predictive
alues of 91%, 85%, 85%, and 91%, respectively. Further
tudies are needed to validate whether the instantaneous
ave-free ratio provides a drug-free index of stenosis sever-
ty comparable to FFR.
ypercholesterolemia and metabolic syndrome. Serum
roprotein convertase subtilisin kexin 9 (PCSK9) binds to
ow-density lipoprotein receptors (LDLR), increasing serum
ow-density lipoprotein cholesterol (LDL-C). SAR236553 is
fully human monoclonal antibody to PCSK9. A Phase
double-blind, parallel-group, placebo-controlled trial
andomized 183 patients with LDL-C 100 mg/dl on
table-dose atorvastatin 10, 20, or 40 mg for 6 weeks to
everal dosing regimens of SAR236553 (35). SAR236553
emonstrated a clear dose-response relationship with
0% to 72% LDL-C lowering and substantially reduced
on– high-density lipoprotein cholesterol, apolipoprotein
, and lipoprotein(a) [Lp(a)]. SAR236553 was generally
ell tolerated.
Serum levels of resistin, an adipose tissue-derived adipo-
ine, are increased in human obesity, are positively corre-
ated with atherosclerotic cardiovascular diseases, and
own-regulate hepatocyte LDLR expression substantially
y 40% in obesity. A key mechanism by which human
esistin inhibited LDLR levels, was by increased cellular
xpression of PCSK9, which enhances intracellular LDLR
ysosomal degradation. Resistin diminished statin-mediated
p-regulation of the LDLR by 60%, implicating resistin in
he relative ineffectiveness of statins in selective target
opulations (36). These results reveal for the first time that
esistin is a highly attractive therapeutic target in amelio-
ating elevated serum low-density lipoprotein and, thereby,
therosclerotic cardiovascular diseases in obese humans.
A study aimed to examine the effect of resolution from
etabolic syndrome (MetS) between youth and adulthoodn carotid artery intima-media thickness (IMT) and type 2
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with MetS in youth and adulthood were at 3.4 times the risk
of T2DM in adulthood compared with those that did not
have MetS at either time-point, whereas those that had
resolved their youth MetS status by adulthood showed
similar risk to those that did not have MetS at either
time-point (p  0.20 for all comparisons). Although youth
with MetS are at increased risk of adult high IMT and
T2DM, these data indicate that the resolution of youth
MetS by adulthood can go some way to normalize this risk
to levels seen in those who have never had MetS.
The role of high-density lipoprotein cholesterol in pre-
dicting cardiovascular events remains unsettled. Therefore,
Mackey et al. (38) evaluated the independent association of
high-density lipoprotein (HDL) cholesterol (C) and particle
(P) concentrations with carotid IMT and incident coronary
artery disease. Both HDL-C and HDL-P correlated with
each other and were associated with an increased coronary
disease hazard ratio of 0.74 and 0.70, respectively. However,
when adjusted for each other and LDL particle concentra-
tion, only HDL-P remained independently associated with
carotid IMT and coronary heart disease. In an accompany-
ing editorial, deGoma and Rader (39) indicated that the
more consistent inverse association between endpoints and
HDL-P in this study suggests that direct quantification of
the concentration of HDL-P may be useful to refine
cardiovascular risk.
Patients with human immunodeficiency virus (HIV) on
antiretroviral therapy are at increased risk of atherosclerosis
due to metabolic disorders. Therefore, Lazzaretti et al. (40)
studied whether dietary intervention could prevent the
dyslipidemia associated with antiretroviral therapy in HIV.
The diet administered was that recommended by the
National Cholesterol Education Program, and the results
clearly indicated a beneficial effect as evidenced by a reduc-
tion in plasma cholesterol from 190 to 151 mg/dl and LDL
from 106 to 85. In an accompanying editorial, Stein (41)
comments that nutritional interventions can prevent adverse
changes in the lipid profile of HIV-infected patients who
are beginning highly antiretroviral therapy, and emphasize
the importance of nutritional interventions at this time.
Hypertension and renal denervation. A study investi-
gated the effect of catheter-based renal sympathetic dener-
vation (RD), not only on BP, but also on left ventricular
hypertrophy and systolic and diastolic function in patients
with resistant hypertension (42). Forty-six patients under-
went bilateral RD, and 18 patients served as controls.
Besides reduction of systolic and diastolic blood pressure
(27.8/8.8 mm Hg at 6 months, p  0.001), RD
significantly reduced left ventricular (LV) mass and im-
proved diastolic function, which might have important
prognostic implications in patients with resistant hyperten-
sion at high cardiovascular risk.
Carotid and peripheral artery disease. The COBRA
(Comparing Two Methods of Expanding Stents Placed in
Legs of Diabetics With Peripheral Vascular Disease) trial(43), a prospective, multicenter, randomized, controlled
clinical trial of diabetic patients, investigated whether post-
dilation of superficial femoral artery nitinol self-expanding
stents using a cryoplasty balloon reduces restenosis com-
pared with a conventional balloon. Inclusion criteria in-
cluded symptoms and superficial femoral artery lesions
requiring implantation of stents 5 mm in diameter and
60 mm in length. Primary endpoint was binary restenosis
at 12 months. Seventy-four patients were enrolled with 90
stented superficial femoral artery lesions. Mean lesion
length was 148 mm, mean stented length was 190 mm,
mean stent diameter was 6.1 mm, and 50% of the lesions
were total occlusions. At 12 months, binary restenosis was
significantly lower in the cryoplasty group (29.3% vs. 55.8%,
p  0.01; odds ratio: 0.36.
The YUKON-BTX study (YUKON-Drug-Eluting
Stent Below the Knee–Randomised Double-Blind Study)
(44) extended the follow-up period of a prospective, ran-
domized, multicenter, double-blind trial comparing
polymer-free SES with placebo-coated BMS in the treat-
ment of focal infrapopliteal de novo lesions. The main study
endpoint was the event-free survival rate. The mean target
lesion length was 31  9 mm. Thirty-five (23.3%) patients
died during a mean follow-up period of 1,016 days. The
event-free survival rate was 65.8% in the SES group and
44.6% in the BMS group (log-rank p  0.02). Amputation
rates were 2.6% and 12.2% (p  0.03), and TVR rates were
9.2% and 20% (p  0.06), respectively. Long-term event-
ree survival, amputation rates, and changes in Rutherford-
ecker class after treatment of focal infrapopliteal lesions
re significantly improved with SES in comparison with
MS.
Randomized trials comparing filter-protected carotid ar-
ery stenting (CAS) with carotid endarterectomy revealed a
igher periprocedural stroke rate after CAS (45). Proximal
alloon occlusion may be more effective in preventing
erebral embolization during CAS than filters. Patients
n  62) undergoing CAS with cerebral embolic protection
or internal carotid artery stenosis were randomly assigned
o proximal balloon occlusion or filter protection. The
rimary endpoint was the incidence of new cerebral isch-
mic lesions assessed by diffusion-weighted magnetic reso-
ance imaging. Compared with filter protection, proximal
alloon occlusion resulted in a significant reduction in the
ncidence of new cerebral ischemic lesions (45.2% vs. 87.1%,
 0.001). Lesions in the contralateral hemisphere were
found in 29.0% and 6.5% of patients (filter vs. balloon
occlusion, respectively, p  0.047). In this randomized trial
of patients undergoing CAS, proximal balloon occlusion as
compared with filter protection significantly reduced the
embolic load to the brain.
Utilizing the National Cardiovascular Data Registry
(NCDR) CARE Registry, Hawkins et al. (46) developed
and validated a pre-procedural risk quantification score to
predict inpatient risk of stroke or death after carotid artery
stenting (n  11,122 procedures; 271 events). Independent
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stroke, age, symptomatic lesion, atrial fibrillation, and ab-
sence of prior ipsilateral carotid endarterectomy. The model
had moderate discriminatory ability (C-statistic 0.71) re-
gardless of symptomatic status or angiographic variables.
The NCDR CAS score using 6 clinical variables predicts
in-hospital stroke/death following carotid artery stenting.
In an interesting viewpoint, Gress (47) raises the question
of the significance of asymptomatic diffusion-weighted im-
aging abnormalities seen on cerebral magnetic resonance
imaging in up to 30% of patients after carotid artery stenting
or endarterectomy. Could these be signs of acute ischemic
injury that predispose to long-term neurological sequelae?
The author calls for more research on the subject, especially
in light of the vast number of cardiovascular angiographic
procedures performed annually.
Lu et al. (48) report on their series of 41 consecutive
patients with ascending aortic arch dissection of whom 15
(10 with chronic dissection and 5 with acute) were judged to
be poor surgical candidates. All 15 of these patients were
successfully treated by endovascular techniques and place-
ment of stent grafts. At a median follow-up of 26 months
(range 16 to 35 months), there was no mortality and only 1
patient required reintervention. This provides an alternative
treatment option for the inoperable patient with ascending
aortic arch dissection.
Stabile et al. (49) treated 39 consecutive patients with
in-stent restenosis (lesion length 82.9  78.9 mm) of the
superficial femoral artery with the paclitaxel drug-eluting
balloon (IN.PACT, Medtronic, Minneapolis, Minnesota).
There were no procedural complications, 100% procedural
success, and 12-month primary patency of 92.1% and
secondary patency 100%. These findings are promising
because contemporary treatment of in-stent restenosis of the
superficial femoral artery has been limited due to high
recurrent restenosis rates.
Scheinert et al. (50) randomized 200 patients (lesion
length 27  21 mm) with critical limb ischemia to infrapo-
pliteal sirolimus-eluting stent versus percutaneous balloon
angioplasty. At 1 year, lower angiographic restenosis (22.4%
vs. 41.9%, p  0.019), and greater vessel patency (75.0% vs.
57.1%, p  0.025), but similar rates of death, repeat
revascularization, and index-limb amputation rates, were
observed with sirolimus-eluting stents. This offers a poten-
tially superior option to balloon angioplasty alone for
below-the-knee lesions in critical limb ischemia.
Rogers et al. (51) evaluated the safety and feasibility of
zotarolimus-eluting stent implantation in focal atheroscle-
rotic lesions of the internal pudendal arteries among 30 men
with erectile dysfunction and suboptimal response to
phosphodiesterase-5 inhibitors. In this first-in-man ZEN
trial, procedural success was 100%, and there were no major
adverse events at 6-month follow-up. The primary feasibil-
ity endpoint (International Index for Erectile Dysfunction
improvement4) at 3 months was achieved in 59.3% in the
intention-to-treat cohort and 68.2% in the per protocolcohort. Binary restenosis was observed in 34.4% and 30.8%
of lesions in the 2 groups, respectively. In an accompanying
editorial, Shishehbor and Philip (52) caution that the use of
drug-eluting stents for the treatment of erectile dysfunction
remains investigational, but this study sets the stage for an
appropriately powered randomized clinical trial.
Antiplatelet therapy. The RESET (REal Safety and Ef-
ficacy of a 3-month dual antiplatelet Therapy following
E-ZES implantation) trial (53) evaluated shorter duration
(3 months) dual antiplatelet therapy (DAPT) after DES
implantation in 2,117 randomly assigned patients with
coronary artery stenosis into 2 groups according to DAPT
duration and stent type: 3-month DAPT following En-
deavor zotarolimus-eluting stent (E-ZES) implantation (E-
ZES  3-month DAPT) versus 12-month DAPT follow-
ing the other DES implantation (standard therapy). The
primary endpoint occurred in 40 (4.7%) patients assigned to
E-ZES  3-month DAPT compared with 41 (4.7%)
patients assigned to the standard therapy (p  0.001 for
noninferiority). The composite rates of any death, MI, or
stent thrombosis were 0.8% and 1.3%, respectively, stent
thrombosis rates were 0.2% and 0.3%, respectively (p 
0.65), without its further occurrence after cessation of
clopidogrel in the E-ZES_3-month DAPT group. The
rates of TVR were 3.9% and 3.7%, respectively; E-ZES 
3-month DAPT was noninferior to the standard therapy
with respect to the occurrence of the primary endpoint.
Another study assessed the risk associated with DAPT
discontinuation, and specifically, temporary discontinua-
tion, during the first year after DES implantation (54). A
total of 1,622 consecutive patients undergoing DES im-
plantation were followed up at 3, 6, 9, and 12 months to
record the 1-year antiplatelet therapy discontinuation
(ATD) rate, the number of days without DAPT, and the
rate of 1-year major cardiac events. One hundred seventy-
two (10.6%) patients interrupted at least 1 antiplatelet drug
during the first year after DES implantation. Most (64.5%)
interrupted DAPT temporarily (median: 7 days). Discon-
tinuation was followed by ACS in 7 (4.1%; a similar rate of
MACE to that in patients without ATD). ATD was not
independently associated with 1-year MACE. ATD within
the first year and beyond the first month after DES is not
exceptional, is usually temporary, and does not appear to
have a large impact on risk.
The ISAR-REACT 4 (Intracoronary Stenting and An-
tithrombotic Regimen: Rapid Early Action for Coronary
Treatment-4) platelet substudy aimed to determine the
relevance of high on-clopidogrel treatment platelet reactiv-
ity (HPR) in non–ST-segment elevation MI patients that
received abciximab with unfractionated heparin or bivaliru-
din during PCI (55). For abciximab with unfractionated
heparin, the incidence of the efficacy endpoint (death, MI,
urgent TVR) was similar in HPR versus no-HPR patients
(9.4% vs. 6.7%). For bivalirudin, the incidence of the efficacy
endpoint was significantly higher in HPR versus no-HPR
patients (22.0% vs. 5.0%; odds ratio: 5.4; p  0.0001). For
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this platelet substudy, the impact of HPR on clinical
outcomes may depend on the type of adjunctive antithrom-
botic therapy used during PCI.
In a prospective, single-center, single-blind study, 44
ACS patients with HPR while on clopidogrel 24 h post-
PCI were randomized to either ticagrelor 90 mg twice daily
or prasugrel 10 mg once daily for 15 days with a crossover
directly to the alternate treatment for another 15 days (56).
HPR was defined as platelet reactivity units (PRU) 235 as
assessed by the VerifyNow P2Y12 function assay (Accumet-
rics, San Diego, California). The primary endpoint of
platelet reactivity at the end of the 2 treatment periods was
lower for ticagrelor (32.9 PRU) compared with prasugrel
(101.3 PRU). The secondary endpoint of HPR rate was 0%
for ticagrelor and 2.4% for prasugrel (1 of 42, p  0.5). No
patient exhibited a major bleeding event in either treatment
group. In patients with ACS exhibiting HPR while on
clopidogrel 24 h post-PCI, ticagrelor produces a signifi-
cantly higher platelet inhibition compared with prasugrel.
The GIFT (Genotype Information and Functional Test-
ing Study) study sought to evaluate the influence of single
nucleotide polymorphisms (SNPs) on the pharmacody-
namic effect of high- or standard-dose clopidogrel after PCI
(57). DNA samples obtained from 1,028 patients were
genotyped for 41 SNPs in 17 genes related to platelet
reactivity. After adjusting for clinical characteristics,
CYP2C19*2 was significantly associated with HPR at 12 to
24 h, 30 days, and 6 months after PCI, whereas PON1,
ABCB1 3435 C¡T, and other candidate SNPs were not.
Carriers of 1 and 2 reduced-function CYP2C19 alleles were
significantly more likely to display persistently high on-
treatment reactivity (OTR) at 30 days and 6 months,
irrespective of treatment assignment. The portion of the risk
of persistently high OTR at 30 days attributable to reduced-
function CYP2C19 allele carriage was 5.2% in the patients
andomly assigned to high-dose clopidogrel. CYP2C19, but
ot PON1 or ABCB1, is a significant determinant of the
harmacodynamic effects of clopidogrel, both early and late
fter PCI. In patients with high OTR identified by
latelet function testing, the CYP2C19 genotype provides
limited incremental information regarding the risk of
persistently high reactivity with clopidogrel 150 mg
maintenance dosing.
The effects of different proton pump inhibitors on clopi-
dogrel were studied by Frelinger et al. (58). A cross-over
design was utilized in normal subjects with the evaluation of
platelet activity by VASP, adenosine diphosphate stimula-
tion, and VerifyNow. Clopidogrel active metabolite de-
creases significantly with esomeprazole, but not with dex-
lansoprazole or lansoprazole. Thus, these agents might be
preferable in patients being treated with clopidogrel.
Prior studies have demonstrated that greater reduction of
platelet reactivity with prasugrel reduces events at the cost of
increased bleeding in acute coronary syndrome. Smith et al.
(59) expanded the database of the TRITON-TIMI 38study (Trial to Assess Improvement in Therapeutic Out-
comes by Optimizing Platelet Inhibition with Prasugrel-
Thrombolysis in Myocardial Infarction 38) to characterize
bleeding in patients who receive prasugrel. They demon-
strated that despite causing an increase in observed bleeding,
platelet transfusion, and surgical re-exploration for bleeding,
prasugrel was associated with a lower rate of death after
coronary artery bypass grafting (CABG) compared with
clopidogrel. In a similar study, Trenk et al. (60) examined
the efficacy, safety, and antiplatelet effect of prasugrel in
patients with high on-treatment platelet reactivity after
percutaneous intervention in the TRIGGER-PCI study
(Testing Platelet Reactivity in Patients Undergoing Elective
Stent Placement on Clopidogrel to Guide Alternative Ther-
apy with Prasugrel). In patients with high-platelet reactivity
following loading doses of clopidogrel, prasugrel provided
an enhanced platelet inhibition but did not result in a
reduction of adverse ischemic events after PCI with DES.
Perhaps the most important finding of this study was the
very low rate of adverse events after PCI with current
therapy with either agent, being 0.5%. Given the greater
antiplatelet potency of prasugrel, Price et al. (61) examined
the recovery of platelet function after discontinuation of
these agents in the Recovery Trial. These investigators
observed that after 7 days of either 10-mg prasugrel or
75-mg clopidogrel, 75% of patients returned to baseline
reactivity within 5 days with clopidogrel but required 7 days
with prasugrel. These data provide strong support for the
recommendation to delay major surgery for this period of
time for the individual antiplatelet agents. Tello-Montoliu
et al. (62) administered 10-mg, 30-mg, and 60-mg doses of
prasugrel to test the pharmacodynamic effects of reloading
dose of prasugrel in patients already on maintenance ther-
apy. They found that the 60-mg dose was associated with
faster and greater platelet inhibition, therefore establishing a
recommendation for reloading of this agent.
Sachdeva et al. (63) studied the impact of clopidogrel
discontinuation in patients undergoing saphenous vein graft
PCI. In a cohort study of 603 patients who underwent vein
graft PCI from 2000 to 2009, 411 patients were event free
at the time of clopidogrel cessation. After multivariable
analysis, the incident rate ratio (95% confidence interval
[CI]) for death and death/myocardial infarction 0 to 90 days
after clopidogrel discontinuation compared with 91 to 365
days was 2.33 (1.32 to 4.11) and 2.58 (1.64 to 4.07),
respectively. Therefore, a clustering of ischemic events is
observed soon after clopidogrel discontinuation in patients
undergoing vein graft PCI.
Previous modeling data have suggested that prasugrel 5
mg in low body weight patients would be noninferior to
prasugrel 10 mg in high body weight patients. In the
FEATHER (Comparison of Prasugrel and Clopidogrel in
Low Body Weight Versus Higher Body Weight With
Coronary Artery Disease) study, Erlinge et al. (64) per-
formed a blinded 3-period cross-over study in stable coro-
nary artery disease (CAD) patients being treated with
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clopidogrel 75 mg to low body weight (56.4  3.7 kg, n 
34) and high body weight (84.7 14.9 kg, n 38) subjects.
edian maximal platelet aggregation by light transmission
ggregometry (primary endpoint) for prasugrel 5 mg in low
ody weight patients (47.0%) was noninferior to the 75th
ercentile for prasugrel 10 mg in high body weight patients
57.1%), and mean maximal platelet aggregation was simi-
ar. This pharmacodynamic study supports the use of
rasugrel 5 mg in low body weight patients.
Singla et al. (65) provided a “state of the art” review
egarding the risks of adverse ischemic and bleeding events
fter noncardiac surgery in patients with previous PCI.
hey point out the consensus in the literature regarding the
igh risk of stent thrombosis in patients undergoing non-
ardiac surgery with either bare-metal or drug-eluting stents
n the first 4 weeks after PCI. Otherwise, there is paucity of
vidence-based data on the best management of antiplatelet
herapy for noncardiac surgery beyond the first month after
CI. The best current treatment algorithm based on con-
emporary data is to delay elective noncardiac surgery
eyond 1 year after PCI with drug-eluting stents and
eyond 1 month after PCI with a bare-metal stent. For
atients requiring noncardiac surgery before that time,
spirin and preferably dual antiplatelet therapy should be
ontinued through the surgery.
With the availability of multiple new antithrombotic
gents, the question of comparative efficacy and safety when
sed for stroke prevention and atrial fibrillation (AF)
egged to be answered. Therefore, Lip et al. (66) carried out
ndirect comparisons for the oral direct thrombin inhibitor
abigatran and the oral factor Xa inhibitors rivaroxaban and
pixaban compared with warfarin for stroke prevention in
F. Acknowledging the limitations of indirect comparison,
hey reported no profound significant differences in efficacy
etween the apixaban and dabigatran or rivaroxaban. Dab-
gatran 150 mg twice daily (BID) was superior to rivaroxa-
an for some efficacy endpoints, whereas major bleeding was
ignificantly lower with dabigatran 150 BID or apixaban. In
n accompanying editorial (67), Cannon and Kohli point
ut that indirect comparisons are fraught with a potential
anger, and can only serve to be hypothesis generating.
Given the bleeding risk with antithrombotic therapy, Apos-
olakis et al. (68) compared several risk-prediction scores for
leeding with anticoagulation. Using the data from the
MADEUS (Evaluating the use of SR 34006 compared to
arfarin or acenocoumarol in patients with atrial fibrillation) trial,
hey compared the HEMORR2HAGES, the ATRIA and the
AS-BLED risk scores in patients with atrial fibrillation.
lthough the authors observed that the HAS-BLED score
as superior to the other 2, the most compelling conclusion
rom this study was that none of the risk scores were of great
alue in predicting clinically relevant bleeding. In regard to
isk, brief correspondence from Price et al. (69) reported 2
atients in whom thrombosis of prosthetic heart valves was
ssociated with the conversion from warfarin to treatment habigatran at usual doses. Until extensive studies evaluating
he role of dabigatran in patients with prosthetic valves are
ompleted, there is no approval for using this agent.
eart failure. Many heart failure (HF) and reduced ejec-
ion fraction (HFrEF) patients have or develop worsening
enal function (WRF) over time, and there is uncertainty
mong clinicians whether aldosterone receptor antagonists
ARAs) should be initiated and/or maintained in the face of
RF. A study by Vardeny et al. (70) analyzing results from
he RALES trial (Randomized Aldactone Evaluation
tudy) in 1,658 patients with New York Heart Association
unctional class III or IV HF and an ejection fraction35%
ddressed these issues. They found that individuals with
educed baseline estimated glomerular filtration rate
eGFR) exhibited similar relative risk reductions in all-cause
eath and the combined endpoint of death or HF hospital-
zation as those with a baseline eGFR 60 and greater
bsolute risk reduction compared with those with a higher
aseline eGFR. WRF was associated with an increased
djusted risk of death in the placebo but not the spirono-
actone group. In an accompanying editorial (71), Kiernan
nd Konstam noted that these data provide reassurance
egarding the relative safety and benefit of ARAs in HFrEF
atients with moderate chronic kidney disease but urged
linicians to continue to use caution in using ARAs.
Chen et al. (72) performed a randomized double-blind
tudy comparing 8 weeks of chronic subcutaneous admin-
stration of B-type natriuretic peptide (BNP) (10 g/kg
ID) (n  20) with placebo (n  20) in patients with
jection fraction 35% and class II to III HF. Chronic SC
NP significantly reduced LV systolic and diastolic volume
ndex and LV mass index, and was associated with a
ignificantly greater improvement of Minnesota Living with
F score, E/e= ratio, and decreased left atrial volume index.
n accompanying editorial by Ahmad and Felker (73)
oted that although these results seem to contradict previ-
us trials in which BNP failed to provide clinical benefits, a
ower dose and more constant exposure to the drug was used
n this pilot, and the authors concluded by endorsing the
eed for future studies.
Although evidence indicates that newer therapies for
reast cancer increase the likelihood of HF, most data have
een collected in trials in which trastuzumab was adminis-
ered to younger patients, often in combination with an-
hracycline chemotherapy. Chen et al. (74) abstracted 16
umor registries linked to Medicare to calculate the 3-year
ncidence of HF or cardiomyopathy (CM) in women age 67
o 94 with early breast cancer. Of the 45,537 patients, they
ound that the incidence rates for HF/CM were higher for
rastuzumab (32.1%) or trastuzumab in combination with
nthracycline (41.9%) compared with no adjuvant therapy
18.1%). They concluded that HF or CM was more
ommon after trastuzumab therapy for older women with
arly breast cancer than in clinical trials that included mostly
ounger women. In an accompanying editorial (75), Leni-
an commented that these results indicated that trastu-
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considered as major risk factors for the development of
HF/CM and that this treatment should identify the patient
as Stage A. Previous studies in-vitro and in animal models
have suggested that statins might be one way to reduce HF
risk in patients receiving chemotherapy. Seicean et al. (76)
identified a cohort of patients with newly diagnosed breast
cancer treated with anthracyline. After adjusting for other
risk factors, they found a significantly lower risk of HF
hospitalization in the patients who received statin therapy
than in controls. They also found that cardiotoxicity risk
factors at the time of diagnosis, baseline ejection fraction,
and trastuzumab use were predictors of incident HF. In an
accompanying editorial, Lenihan (77) commented upon the
growing acceptance that statins may improve cancer out-
comes and that they “appear to be one necessary component
for cancer patients to ready themselves for their cancer war.”
It is not known whether severely ill patients with ad-
vanced heart failure and anemia are likely to respond to iron
alone or whether the addition of erythropoiesis-stimulating
agents (ESA) is also necessary. To address this issue,
Terrovitis et al. (78) randomly assigned 30 iron-deficient
patients with advanced HFrEF to treatment with either the
combination of iron and an ESA or iron alone. There was
a significant increase in hemoglobin that persisted to 3
months without serious adverse effects with either regimen.
The investigators concluded that monotherapy with intra-
venous iron should be regarded as an efficient treatment
option for iron deficiency anemia in patients with advanced
heart failure. Although both cardiopulmonary exercise test-
ing and 6-min walk testing (6MW) have been used to assess
functional capacity in heart failure patients with HFrEF,
there is limited information comparing the 2 tests. Forman
et al. (79) evaluated 2,054 patients who underwent both
tests in the HF-ACTION (Heart Failure: A Controlled
Trial Investigating Outcomes of Exercise TrainNing) study.
They found that in HFrEF patients, cardiopulmonary
exercise testing and 6 MW testing indices were as univariate
predictors for all-cause mortality and all-cause hospitaliza-
tion/mortality. Both indices added only modest prognostic
discrimination to models that included important demo-
graphic and clinical covariates. Logistical restraints often
limit the ability to perform formal tests of exercise capacity
and hospitalized patients may not be able to perform such
tests optimally. Spruit et al. (80) evaluated the extent of
patient reported ability to perform daily activities using the
Duke Activity Status Index and 6MW test distance change
over 1 year and whether such changes affected prognosis in
chronic heart failure patients. In a group of 309 patients,
they found that improved self-reported physical capacity
after 1 year was associated with better prognosis in HF
patients. By contrast, objective measures of improvement
appeared to have limited prognostic value. These findings
support the use of a questionnaire such as the Duke Activity
Status Index to estimate self-reported physical capacity in
daily clinical practice. RSeveral studies deal with issues related to cardiac rate and
rhythm and heart failure. The TARGET trial (Targeted
Left Ventricular Lead Placement to guide Cardiac Resyn-
chronization Therapy) (81) examined the premise that
placement of the left ventricular lead at the site of the latest
contraction away from the scar would confer the best
response to resynchronization (CRT). They randomized
220 patients, were able to place the LV lead in the site of
latest peak contraction in approximately 60%, and found
that group to have a greater number of responders at 6
months (70% vs. 50%, p  0.03) and greater number with
a 15% reduction in LV end-systolic volume (2% vs. 28%).
These data suggest that placing the left ventricular lead for
resynchronization in the segment of latest contraction may
substantially reduce the number of nonresponders to resyn-
chronization therapy. In an accompanying editorial, Ghali
(82) indicates that although the findings of this trial may not
mandate placement in the most delayed viable segment
when CRT is being considered, they do indicate that some
reason for not following this strategy should be existent. A
substudy of the SHIFT (Systolic Heart Failure Treatment
with the If inhibitor ivabradine Trial) study addresses the
mportant question of whether or not the ability of ivabra-
ine to have a beneficial effect in congestive heart failure
atients was influenced by the dose of beta-blocker drug
83). Patients in SHIFT were grouped according to beta-
locker doses:25%, 25% to 50%, 50% to 100%, and 100%.
he primary endpoint of heart failure hospitalization was
educed by ivabradine in all subgroups. Thus, the authors
oncluded that the magnitude of heart rate reduction by
eta-blocker plus ivabradine, rather than background beta-
locker dose, primarily determines the subsequent effect on
utcomes. In an accompanying editorial (84), Sarraf and
rancis comment that despite the observation that reduc-
ion in heart rate appears to be the most important outcome,
t would be well to avoid “indication creep” in which
vabradine was substituted for beta-blockers in patients who
arbor mild but relative contraindications to beta-blockers.
A major advance in the optimal management of patients
ith continuous–flow left ventricular assist devices (LVAD)
as the Columbia Ramp Study by Uriel et al. (85). This
aper described a protocol applied in patients with LVADs
o optimize the continuous-flow rate and detect device
alfunction. The rotational rate of the device was increased
n increments of 400 rpm from 8,000 to 12,000 rpm while
V end-diastolic dimension, aortic valve opening, valve
nsufficiency, blood pressure, and LVAD parameters were
ecorded. The results were subsequently plotted and linear
unction slopes developed. The rotational speed was
hanged on the basis of these tests in 61% of patients,
hereas device thrombosis was confirmed in 8 of 10 cases
uspicious by the results of the test. In an accompanying
ditorial, Rogers and Milano (86) comment that as mechan-
cal circulatory support continues to mature, development
nd validation of objective optimization approaches like the
amp Study are needed.
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patients with Brugada syndrome in the PRELUDE
(PRogrammed ELectrical stimUlation preDictive valuE)
study, and identified the most significant predictors of
ventricular arrhythmias to identify good candidates for an
implantable cardioverter-defibrillator. This was a prospec-
tive registry study, and patients underwent programmed
electrical stimulation in an attempt to induce potentially
life-threatening arrhythmias. The authors found that pro-
grammed electrical stimulation of ventricular arrhythmias
was not useful in identifying Brugada patients at risk for
future arrhythmias. The useful variables were a spontaneous
type 1 Brugada pattern on the electrocardiogram (ECG), a
history of syncope, a ventricular effective refractory period
200 ms at electrophysiology study, and QRS fragmenta-
tion on ECG. This study also identified 2 new independent
risk factors, namely, a short ventricular refractory period
(which could only be determined at electrophysiological
study) and QRS fractionation on ECG. This study suggests
that invasive electrophysiological testing may not be warranted
at all in patients with Brugada syndrome to predict risk of
ventricular arrhythmias and need for ICD implantation.
Brignole et al. (88) reported on a prospective observa-
tional study of ICD implantation with or without defibril-
lation threshold testing in 2,120 consecutive patients in the
SAFE-ICD (SAFEty of Two Strategies of ICD Manage-
ment at Implantation) study. Patients were followed up to
24 months for a primary endpoint of severe complications at
ICD implant and sudden cardiac death or resuscitation (88).
In this population, which may have been low risk to begin
with, there was no difference in primary endpoint at the end
of follow-up, and there was no difference in mortality from
any cause. The authors acknowledge that the sudden death
rate was low and may have been insufficient to show a
difference in the clinical effect of defibrillation threshold
testing, although the shock rate was sufficiently high. In
addition, as noted in the accompanying editorial by Estes
(89), this study may not have addressed a higher-risk
population with high DFTs, and this study did not follow
patients beyond 2 years, and in some patients shocks do not
occur until after 2 years follow-up.
Ganesan et al. (90) reviewed all-cause and cardiovascular
mortality published data from 2004 to 2010 on patients with
atrial fibrillation undergoing CRT, with (n  339) or
ithout (n  429) atrioventricular (AV) node ablation. The
uthors concluded that AV node ablation in patients with
F undergoing CRT reduced all-cause mortality with a risk
atio of 0.42, and cardiovascular mortality with a risk ratio of
.44, and improved mean New York Heart Association
unctional class with a risk ratio of0.52. AV node ablation
ncreases the percentage of biventricular pacing, which was
oted to be nearly 100% in the AV node ablation patients,
ut varied from only 82% to 96.5% in the patients without
V node ablation. An accompanying editorial by Gasparini
nd Galimberti (91) emphasize the apparent benefit of AV
ode ablation in patients with AF undergoing CRT and trecommend that it be “considered a fundamental of a
combined strategy to obtain the best results of CRT in this
complex HF population.”
Old Nordkamp et al. (92) reported their initial experience
using a totally subcutaneous implantable cardioverter defi-
brillator (SQ-ICD), ushering in a new era in ICD therapy.
They implanted SQ-ICDs in a total of 113 patients out of
a total of 1,300 patients who underwent ICD implantation
without a need for bradycardia pacing. Only 6 patients had
a secondary prevention indication. The mean LV ejection
fraction (LVEF) was 41%. During 18  7 months follow-
p, no patients died from arrhythmic causes. Eight patients
ad a total of 9 episodes of spontaneous sustained ventric-
lar tachycardia (VT) and 36 episodes of spontaneous
entricular fibrillation, all episodes were appropriately de-
ected, and shock therapy was successful in 98% of these
pisodes. Inappropriate shocks occurred in 15 (13%) pa-
ients, mostly due to T-wave oversensing or double count-
ng, most of which was solved by device programming.
omplications occurred in 16 (14%) patients, including SQ
ead migration, lead erosion, and device infections requiring
xplantation, although the complication rate decreased
ver time with operator experience. This brief report of
he new SQ-ICD demonstrates its feasibility, effective-
ess, and limitations.
trial fibrillation mechanisms. The growing epidemic of
trial fibrillation (AF) continues to exact substantial public
ealth implications (93). Several papers in the Journal in
012 provided mechanistic insights for AF that may trans-
ate into novel therapy. Swartz et al. (94) examined the
elationship between serum markers for collagen I and III
ynthesis, left atrial (LA) fibrosis and post-operative AF. In
4 patients undergoing cardiac surgery without prior AF
istory, 18 patients developed post-operative AF. Those
ho developed AF had greater LA fibrosis with higher LA
RNA transcripts for collagen I and III, and higher serum
arkers for collagen synthesis, with a linear correlation
etween LA fibrosis and these markers. Clearly, these
esults require further validation, but add to the growing
ink between AF and fibrosis (95), dynamic conduction
lowing at the site where human AF initiates (96), and the
ormation of AF-sustaining rotors in humans (97), whose
blation may substantially increase the efficacy of conven-
ional ablation. These data also support recent data that
ven patients with “lone AF” exhibit detectable conduction
lowing compared with controls (98).
In complementary studies, Deftereos et al. (99) reported
randomized controlled trial to test whether the anti-
nflammatory colchicine may reduce AF recurrence after
ulmonary vein (PV) isolation in patients with paroxysmal
F. The authors randomized 161 patients to a 3-month
ost-ablation course of colchicine or placebo. In the first 3
onths post-ablation, freedom from AF was 84% in the
olchicine group versus 66.5% in the placebo limb. The
uthors concluded that (expected) reductions in inflamma-
ory markers (C-reactive protein and interleukin-6) from
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accompanying editorial (100), this study is intriguing but
requires additional follow-up because AF often recurs late
after ablation (101).
Improved results from catheter ablation of atrial fibril-
lation. Catheter ablation is increasingly applied (102), but
methods to improve its success (particularly after 1 proce-
dure) (103) and reduce its complications (104) are needed.
Several reports focused on new approaches for the catheter
ablation of AF. The CONFIRM (Conventional ablation
with or without Focal Impulse and Rotor Modulation) trial
(97) showed for the first time that human AF may be
sustained after it is triggered by stable electrical spiral waves
(rotors) or focal sources. Targeted ablation at pre-identified
patient-specific sources alone (focal impulse and rotor mod-
ulation [FIRM]) demonstrated, uniquely, that AF could be
acutely terminated and rendered noninducible. In 92 pa-
tients, FIRM-guided therapy had 82.4% freedom from AF
compared with 44.9% in conventional (FIRM-blinded)
patients at up to 2 years of follow-up using rigorous
implanted ECG monitoring. The short-term results of the
CONFIRM trial have recently been validated by indepen-
dent external groups (105).
In another novel approach to ablation, Pokushalov et al.
(106) reported on “hybrid” therapy adding renal denervation
to conventional pulmonary vein isolation (PVI). The au-
thors randomized 27 patients with paroxysmal AF and
resistant hypertension to PVI with and without renal artery
denervation achieved using routine ablation catheters. Pa-
tients in the hybrid limb had 69% freedom from AF (9 of
13) versus 29% (4 of 14) in the PVI-only limb, with
corresponding reductions in hypertension. The authors
concluded that renal artery denervation reduces systolic and
diastolic blood pressure in patients with drug-resistant
hypertension and reduces AF recurrences when combined
with PVI.
A major limitation of PV isolation for AF is that durable
isolation of the PVs is difficult to achieve, and PV recon-
nection is seen in patients with (107,108) and without (109)
recurrent AF. Kowalski et al. (110) uniquely examined PV
histopathology in patients undergoing surgical PV isolation
after previously failed percutaneous PVI. After confirming
that PVs often reconnected, the authors reported that PVs
may be electrically isolated despite visible ablation gaps and
provided evidence for continued injury (nuclear pyknosis
and myocytolysis) that may explain late AF recurrence
(100). Another interesting surgical study by Pison et al.
(111) described “hybrid” AF ablation, combining thoraco-
scopic with percutaneous ablation to achieve PVI with
varying additional lesions, including box lesions around the
veins, a mitral isthmus line, a left atrial roof line, and right
atrial bicaval line. In this single-center, single-arm, obser-
vational study in 26 patients (58% paroxysmal AF, 38%
prior procedures), the authors reported an 83% procedural
success. An editorial by Calkins (112) discusses how, despite
the many additional “patient-tailored” lesions that compli-cate its mechanistic interpretation and obvious technical
difficulties of this potentially laborious approach, the study
represents a pioneering approach that may have value in
some patients.
It is well recognized that metabolic syndrome and obesity
may partly explain the epidemic in AF. Two reports in the
Journal show that patients with obesity and the metabolic
syndrome exhibit higher levels of inflammatory markers
(113) and shorter atrial refractory periods (114) that may
facilitate AF and explain the lower success rate of conven-
tional PV isolation in these populations. Further mechanis-
tic studies are required to elucidate the precise mechanisms
of ablation failure in these patients.
A study by Shah et al. (115) reports the outcomes in more
than 4,000 patients undergoing catheter ablation for atrial
fibrillation in the United States. The authors report a 5%
incidence of periprocedural complications. Rates of read-
mission for recurrent atrial arrhythmias were 21.% by 1 year
and nearly 30% by 2 years. These data suggest that early
failure after ablation for atrial fibrillation is common and
that better patient selection and quality assurance may be
necessary to improve outcomes.
Novel oral anticoagulants for AF. One of the major
developments in treating AF patients is the availability of
novel oral anticoagulants. In a brief report from the RE-LY
(Randomized Evaluation of Long-Term Anticoagulation
Therapy) study, Flaker et al. (116) reported that dabigatran
has similar efficacy for patients with permanent (longstand-
ing persistent) AF, persistent AF, and paroxysmal AF. In
the context of anticoagulation during AF ablation, Lak-
kireddy et al. (117) compared dabigatran, held only on the
morning prior to ablation, against uninterrupted warfarin in
290 patients undergoing AF ablation at 8 centers. In 145
patients in each limb, the authors reported 3 thromboem-
bolic complications (2.1%) in the dabigatran group versus
none in the warfarin group (p  0.25), but a higher major
bleeding rate (6% vs. 1%; p  0.019), total bleeding rate
(14% vs. 6%; p  0.031), and composite of bleeding and
thromboembolic complications (16% vs. 6%; p  0.009) in
dabigatran versus warfarin patients. The authors concluded
that dabigatran peri-AF ablation procedures increases the
risk of bleeding compared with uninterrupted warfarin. A
comprehensive editorial by Knight (118) discussed this
strategy in comparison to other studied anticoagulation
strategies during AF ablation.
Treatment of malignant ventricular arrhythmias. Sud-
den cardiac arrest from ventricular tachyarrhythmias is the
leading cause of death in the Western world. Lethal
ventricular arrhythmias are typically re-entrant, and require
slow conduction velocity and regions of short repolarization.
Few strategies improve conduction velocity. A report by
Greener et al. (119) showed that gene transfer of con-
nexin43 in a porcine model of ventricular infarction could
improve conduction velocity and prevent the induction of
ventricular arrhythmias. An editorial commentary by Saffitz
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cations of this discovery.
Patients with intractable ventricular arrhythmias (“elec-
trical storm”) are very difficult to treat. Di Biase et al. (121)
reported on a novel method to minimize the chance of
partial-thickness lesions that may leave viable tissue, by
generating transmural ablation lesions (“homogenization”)
via epicardial mapping and ablation as well as endocardial
ablation. In 92 consecutive patients with ischemic cardio-
myopathy and electrical storm, the authors performed ab-
lation either confined to the endocardial surface, or via
endocardial and epicardial ablation. During follow-up of
25  10 months, post-ablation VT/ventricular fibrillation
recurrence was lower in the homogenization group (19%)
compared with those receiving traditional endocardial abla-
tion alone (47%). This study is of particular interest because
epicardial ablation is typically less frequently performed in
patients with ischemic versus nonischemic cardiomyopathy
(122).
There has been much interest in the role of the auto-
nomic nervous system to modulate ventricular arrhythmias.
An intriguing study by Han, et al. (123) examined changes
in left stellate ganglionic nerve activity (SGNA) and left
thoracic vagal nerve activity after acute MI. The authors
implanted radio transmitters to record the SGNA, vagal
nerve activity, and electrocardiograms in 9 ambulatory dogs
before, then after myocardial infarction. The authors found
that MI increased 24-h SGNA and, on autopsy, increased
nerve staining for growth-associated protein 43 and synap-
tophysin. The authors concluded that MI causes significant
remodeling of extracardiac autonomic nerve activity, which
may contribute to ventricular arrhythmias. Prior reports
suggested that left cardiac sympathetic denervation could
be used to treat patients with electrical storm (124). A
brief report in the Journal by Ajijola et al. (125) extends
hat literature by showing that bilateral cardiac sympa-
hetic denervation may be effective in managing electrical
torm when left cardiac sympathetic denervation has been
nsuccessful.
ardiac imaging. It has been hypothesized that the dura-
ion of left ventricular early systolic lengthening on echo
ould identify patients with significant coronary artery
isease (126). In 86 patients (50% CAD) 2-dimensional
peckle-tracking echo was performed before invasive an-
iography. The duration of early systolic lengthening was
rolonged in the patients with CAD (76  37 ms vs. 38 
3 ms, p  0.001), with a reduced global systolic strain
17.7  3.0% vs. 19.5  2.6%, p  0.003). Of interest,
he duration of early systolic lengthening decreased signif-
cantly after revascularization (from 76 ms to 64 ms, p 
.041).
Coronary artery calcium score has been shown to provide
mportant prognostic information. Various studies further
valuated the use of calcium score for prognosis. The
elation between long-term lipid levels, the lipid genetic risk
core, and the coronary artery calcium scores were evaluated wn the Framingham Heart Study (127). It was shown that
arly and long-term average lipid levels were strongly
ssociated with an elevated calcium score; the lipid genetic
isk score was associated with lipid levels, but was not
redictive of an elevated calcium score.
Another study evaluated the value of risk factors during
dolescence to predict later development of coronary artery
alcifications (128). In 589 individuals, the risk factors were
ssessed over the ages of 12 to 18 years. At the age of 40 to
6 years, the coronary artery calcium score was assessed. It
as shown that elevated LDL-C and systolic blood pressure
evels during adolescence were independent predictors of
oronary artery calcium during adulthood. These findings
mphasize the importance of early prevention and risk factor
odification in childhood (129).
Different studies reported on the clinical value of CT
ngiography. In a large multicenter study (47 centers, 6,198
atients), the value of stress testing to identify obstructive
AD (defined as 50% stenosis) on CT angiography and
nvasive coronary angiography was evaluated (130). The
redictors for a significant stenosis on CT angiography were
ale sex, smoking, older age, hypertension, and typical
ngina; importantly, stress test results were not predictive.
urthermore, in a subgroup of 621 patients, there was a
trong agreement between CT angiography and invasive
ngiography for detection of significant stenoses. In an
ccompanying editorial, it was pointed out that stenosis
everity and stress testing reflect different aspects of coro-
ary artery disease (anatomic and functional), and therefore,
greement may be limited (131).
The relative prognostic merits of CT angiography and
xercise ECG were retrospectively evaluated in 2,977 pa-
ients (132). The median follow-up was 3.3 years, and the
-year cumulative event rate was 3.6%. Both exercise ECG
nd CT angiography improved risk stratification over clin-
cal risk factors. However, CT angiography was predictive
f future risk independent of exercise ECG results; only in
atients with moderate-to-severe stenosis on CT angiogra-
hy did exercise ECG provide additive prognostic value. In
n accompanying editorial, it was emphasized that the role
f exercise ECG and CT angiography in the diagnostic
lgorithm of patients presenting with chest pain and inter-
ediate pre-test likelihood of CAD remains uncertain
133).
A report from the large CONFIRM registry evaluated
he role of CT angiography as gatekeeper for invasive
oronary angiography (134). In 15,207 patients with inter-
ediate pre-test likelihood of CAD, the use of invasive
ngiography (and revascularization) paralleled the severity
f CAD on CT angiography. In patients with mild CAD
n CT angiography, the referral rates for angiography and
evascularization were low (8.3% and 2.5%, respectively).
onversely, in patients with obstructive 3-vessel CAD, the
eferral rates for invasive angiography and revascularization
ere 69.4% and 66.8%, respectively.
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with CT. The prognostic value of contrast delayed enhance-
ment with 64-slice CT after acute myocardial infarction was
evaluated in 102 patients (135). In patients with first acute
myocardial infarction, CT imaging was performed imme-
diately after successful percutaneous coronary intervention
without the use of additional contrast. The size of myocar-
dial contrast delayed enhancement correlated with outcome,
independent of the Thrombolysis In Myocardial Infarction
(TIMI) risk score, left ventricular ejection fraction, and the
total defect score on nuclear perfusion imaging.
Finally, hybrid imaging permits integration of anatomic
and functional (or biological) information and is particularly
useful in the field of molecular imaging. Hybrid positron
emission tomography/computed tomography (PET/CT)
was used in an animal model (pigs) to evaluate changes in
angiotensin II subtype 1 receptor (AT1R) after myocardial
infarction (136). Using the novel AT1R ligand (11C-
R31173), the feasibility of imaging AT1R was shown;
fter infarction, there was an AT1R up-regulation in the
nfracted tissue as compared with the remote area confirmed
n postmortem analysis. The safety and feasibility of the
ET/CT approach to image AT1R was also demonstrated
n humans, although the retention level of 11C-KR31173
was lower than in pigs. Clearly, PET/CT permits imaging
on the molecular level and will become important in the
improved understanding of pathophysiological processes in
health and disease; moreover, visualization of these pro-
cesses will be useful to evaluate and measure therapeutic
effects (137).
In 2012, one of the crucial clinical questions in cardiology
is the role of ischemia in determining the need for revascu-
larization. An interesting paper performed in Korea studied
the impact of ischemia-guided revascularization (IG) based
on the demonstration of perfusion defects by myocardial
perfusion imaging (138). The authors used a registry of
5,340 patients who underwent PCI (n  2,587) or CABG
(n 2,753) and used propensity analysis to compare arteries
with corresponding perfusion defects against those without.
The incidence of major adverse cardiac and cerebrovascular
events (MACE) including death, MI, stroke, or repeat
revascularization was significantly lower in the IG group
(16.2%) than in the non-IG group (20,7%, p  0.001),
suggesting that IG revascularization guided by myocardial
perfusion imaging reduces the rate of MACCE in patients
with CAD. The differences were primarily driven by differ-
ences in repeat revascularization (9.9% vs. 22.8% in the IG
and non-IG groups, respectively, p  0.009) and particu-
larly in patients who had PCI as opposed to CABG. The
paper’s findings were further discussed by Weintraub (139),
who provided a larger context for study interpretation and
potential use in clinical practice.
Myocardial perfusion abnormalities determined by imag-
ing, against which the fractional flow reserve method was
validated, represents the best way to assess the flow-limiting
capability of specific coronary stenoses. This year, a multi- dmodality meta-analysis by Jaarsma et al. (140) addressed the
diagnostic performance of single-photon emission com-
puted tomography (SPECT), cardiac magnetic resonance
(CMR), and PET against invasive coronary angiography.
Pooled sensitivities were 88%, 89%, and 84% for SPECT,
CMR, and PET, with pooled specificities of 61%, 76%, and
81%, respectively. Study characteristics and test character-
istics did not appear to affect these results, indicating that
PET is probably the modality with the strongest diagnostic
profile. Another meta-analysis compared SPECT (8 studies
including 1,755 patients) with rubidium-82 PET (15 stud-
ies including 1,344 patients) performed by McArdle et al.
(141) with pooled sensitivities of 85% versus 90% for
SPECT and PET, respectively, whereas pooled specificities
were 85% and 88%, respectively. The authors conclude that
rubidium-82 PET remains superior to SPECT for the
detection of CAD.
Finally, the important head-to-head comparisons be-
tween 13N-ammonia PET and CMR by Morton et al. (142)
dds significantly to the field of quantitative perfusion
nalysis. The authors studied 41 patients with both imaging
ethods before invasive angiography. CMR and PET
orrelated well for measures of myocardial perfusion reserve
r  0.75), but absolute perfusion correlated less well at rest
r  0.32) and during stress (r  0.37). The authors
oncluded that despite the good correlations on myocardial
erfusion reserve and its utility clinically, significant devel-
pment is still required before absolute perfusion can be
easured accurately by magnetic resonance. In an editorial,
ernard Gerber (143) discussed issues related to the mea-
urement of perfusion reserve noninvasively and the specific
ontribution of this original paper.
Jogiya et al. (144) reported the validation of a novel
-dimensional whole-heart magnetic resonance imaging
MRI) perfusion imaging method against fractional flow
eserve for the detection of obstructive CAD. The authors
ound that state-of-the-art MRI perfusion methods have
1% sensitivity and 90% specificity when compared with
FR and also a good correlation between ischemic burden
y CMR and the Duke Jeopardy Score (r  0.82, p 
.0001). They concluded that state-of-the-art perfusion
tudies can accurately detect obstructive CAD and thus
olds promise for the noninvasive guidance of therapy.
nother study reported the use of blood oxygen level–
ependent (BOLD) MRI at 3-T to evaluate the actual
resence of ischemia in patients with CAD. The prospective
tudy included 60 patients receiving BOLD and first-pass
MR perfusion imaging at rest and adenosine stress versus
nvasive coronary angiography (145). Importantly, the isch-
mic threshold for the BOLD method at 3-T was first
etermined in a preceding study involving 25 patients with
AD. The authors reported a sensitivity of 92% and
pecificity of 72% for the BOLD technique to detect
yocardial ischemia but also to identify obstructive CAD.
nterestingly, segment-based analysis demonstrated evi-
ence of dissociation between oxygenation and perfusion,
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stenosis (r  0.20) than with myocardial perfusion (r 
0.40, p  0.005). The possibility of reaching beyond
anatomic obstruction and perfusion deficits to measure
oxygenation supply/demand disequilibrium directly is in-
deed exciting and may be feasible at higher field strengths.
The paper’s findings are further evaluated in an accompa-
nying editorial comment by Weinsaft and Spincemaille
(146).
In an editorial “Myocardial Viability Imaging: Dead or
Alive?” Wu (147) puts in perspective an important study by
Gerber et al. (148) on the value of myocardial viability
assessment by MRI in the wake of failure to predict clinical
outcomes by other imaging methods used in the STICH
(Surgical Treatment for Ischemic Heart Failure) trial. Ger-
ber et al. studied 144 patients followed for over 3 years and
showed that among patients treated medically, survival was
significantly worse in patients with dysfunctional, but viable
as opposed to nonviable, myocardium (48% vs. 77%, respec-
tively, p  0.02) (148). Conversely, among revascularized
patients, survival was similar whether myocardium was
viable or not (88% vs. 77%, p  NS). Moreover, in
multivariable analysis, the interaction of revascularization
and viability added value (chi-square test: 13.1, p 0.0004)
to other clinical predictors of prognosis. Finally, the hazard
of death remained greater for patients treated medically
than for those treated with revascularization that restored
myocardial viability (HR: 2.5). The authors concluded that
in patients treated medically, the presence of dysfunctional
myocardium assessed by CMR is an independent predictor
of mortality.
The use of contrast-enhanced MRI has evolved rapidly to
address questions of scar sizing and pathophysiology among
patients with nonischemic cardiomyopathies. This year,
Todiere et al. (149) reported the progression of myocardial
fibrosis measured by CMR among patients with hypertro-
phic cardiomyopathy (HCM). A total of 55 HCM patients
underwent 2 CMR examinations separated by an interval of
719 days. In 44 patients, the extent of myocardial fibrosis
increased substantially (1 g), and patients with apical
HCM who had worse heart failure symptoms were partic-
ularly prone to scar augmentation. The authors concluded
that myocardial fibrosis in HCM can progress fast and is
harbinger of worse clinical status. The significance of these
findings is discussed in detail in an accompanying editorial
comment by Bluemke and Yang (150). Klem et al. (151)
report that the evaluation of myocardial scars by MRI
improves the risk stratification of patients being considered
for cardiac defibrillation implantation. The authors showed
that during a median follow-up of 2 years, 137 patients who
underwent clinical evaluation for possible ICD implantation
suffered adverse outcomes at a faster pace if they had
myocardial scar size 5%. Among patients with LVEF
30%, those with significant scarring had a higher risk than
those with minimal or no scarring (HR: 3.9). Interestingly,
those with LVEF 30%, but with minimal scarring byCMR, had risk similar to those with LVEF 30% (p 
0,71). The authors concluded that myocardial scarring
detected by CMR is an independent predictor of adverse
outcomes in patients being considered for ICD placement.
The study results were further discussed by Mewton and
Chevalier (152).
A study by Hachamovitch et al. (153) examined the role
of noninvasive imaging in management in patients with
coronary disease in a prospective registry. About half of the
patients with the most severe abnormalities were not re-
ferred for catheterization, and about one-quarter did not
receive aspirin or a lipid-lowering agent. More patients
undergoing coronary CT angiography were referred for
catheterization after a normal or minimally abnormal study
than those undergoing nuclear perfusion imaging. This
study suggests that noninvasive imaging, particularly CT
angiography, is not used optimally in patients with sus-
pected coronary disease.
Biomarkers. Management of patients presenting with out-
of-hospital cardiac arrest has been difficult due to a lack of
predictors of neurological recovery. To this end, Einav et al.
(154) looked at whether serum s100 beta (s100B) and
neuron-specific enolase could add value in predicting out-
come after out-of-hospital cardiac arrest. They studied 195
patients, and 23% survived to discharge. Patients with good
outcomes had lower levels of s100B and enolase levels,
measured on days 1 and 3. An editorial by Comess et al.
(155) points out that the main 2 things doctors want to
know after arrest are when to cease supportive care and what
the prospects are for recovery with continued care. Although
the study falls short in answering these questions, it lends
support to the idea that biomarkers added to clinical
indicators may reduce the level of uncertainty when making
these important decisions.
Neuropeptide proenkephalin A (PENK-A) is a neuro-
logical marker of disruption of the blood-brain barrier and
has been studied in diseases of the central nervous system.
Doehner et al. (156) measured PENK-A in 189 patients
presenting with acute stroke. Levels were significantly
higher in patients with ischemic stroke compared with
patients with transient ischemic attacks. Additionally, pa-
tients in the highest quartile of PENK-A had increased risk
of mortality (HR: 2.40) and of major adverse cerebrovascu-
lar and cardiovascular events (HR: 2.23). This and other
disruption markers of the blood-brain barrier may be
promising targets for diagnosis of stroke as well as potential
for treatment.
The advantages of measuring levels of microRNAs
(miRNAs) include their stability over time, easy quantifi-
cation, and potential high sensitivity. To this end, Zam-
petaki et al. (157) studied 19 candidate miRNAs in 820
at-risk patients from a population survey of individuals
living in Bruneck, Italy. In subjects with subsequent myo-
cardial infarction, differential coexpression patterns of cir-
culating miRNAs centered on endothelium-enriched
miR-126, with platelets being a large contributor to this
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January 22, 2013:357–85 Highlights from JACC 2012signature. In an accompanying editorial by Engelhardt
(158), it is suggested that more studies of this kind are still
needed in order to better understand the clinical relevance of
these tiny RNA molecules.
Despite aggressive treatments of hypertension and dys-
lipidemia, cardiovascular events remain a challenging prob-
lem. Nadir et al. (159) prospectively studied 300 patients
enrolled in a primary prevention clinic to identify silent
cardiac target organ damage (cTOD) using a combination
of imaging and biomarkers. One or more forms of previ-
ously undetected cTOD were present in 34% of subjects.
BNP 15 pg/ml and high-sensitivity cardiac troponin T
(cTnT) 5.93 ng/l was the best combination of biomarkers
for cTOD with a sensitivity of 87%, negative predictive
value of 90%, and a specificity of 65%. In an editorial,
Richards (160) comments that although this type of phe-
notyping may not be ready for clinical practice, this trial
should help us to design future therapeutic trials by better
defining treatment targets and better case selection for
recruitment to trials.
Whether small elevations of troponins can predict sur-
vival in PCI patients is still under debate. To help answer
this question, Watabe et al. (161) used multidetector com-
puted tomography to study the relation between culprit
plaque characteristics and troponin elevation after PCI.
Positive remodeling and spotty calcification were found to
be statistically significant independent predictors of tro-
ponin elevation. The added attenuation value of 55
Hounsfield units demonstrated a positive predictive value of
95% and a negative predictive value of 90% for troponin rise.
An editorial by Malpeso et al. (162) suggests that validation
studies still need to be done with advanced multidetector
computed tomography and virtual histology IVUS along
with histopathologic features.
Galectin 3 (Gal3) is a beta-galactoside–binding lectin
expressed by activated macrophages that mediates collagen
deposition and subsequent fibrosis. To examine whether
Gal-3 could identify primary prevention candidates at in-
creased risk for heart failure, Ho et al. (163) measured Gal-3
in 3,353 subjects in the Framingham Offspring Cohort.
They demonstrated that the risk of new HF over 8 years
increased by 28% for each standard deviation increase in
log-transformed Gal-3 concentration. An editorial by Mor-
row and O’Donoghue (164) suggests that further investiga-
tion of Gal-3 may lead to advances in our understanding of
organ fibrosis (especially cardiac) and remodeling, leading to
potential new therapies or early use of existing therapies
such as mineralocorticoid antagonists.
High-sensitivity troponins have presented a new “pheno-
type” of a patient with low levels of circulating troponin
indicating subclinical cardiac injury. Rubin et al. (165) used
the ARIC (Atherosclerosis Risk in Communities) study to
examine cTnT as a phenotype of subclinical cardiac disease.
Higher glycosylated hemoglobin was associated with ele-
vated hs cTnT among persons without clinically evident
coronary disease, suggesting that hyperglycemia contributesto myocardial injury beyond atherosclerotic coronary dis-
ease. In an accompanying editorial, de Lemos and Grundy
(166) point out that although some limitations were present,
this study should prompt further exploration of the role of
chronic hyperglycemia in early pathways leading to heart
failure development in both animal and human models.
Prevention, quality, cost-effectiveness. The sequencing
of the human genome and the identification of various
genetic risk markers has renewed interest in the value of a
simple family history of early-onset coronary disease as a
risk predictor (family history is not included in the Fra-
mingham risk calculator). Ranthe et al. (167) linked the
Danish Family Relations Database, which documents kin-
ship of Danish citizens, with the hospital records of the
Danish healthcare system to assess the risk associated with
a family history of early-onset coronary disease. They found
the risk of early-onset coronary disease (60 years of age)
was directly and proportionately related to the number of
close relatives with early-onset disease, and that the rela-
tionship was stronger for first-degree relatives, even after
control for other cardiac risk factors. The specific genetic
factors mediating this association are as yet uncertain, but
this study underscores the value of taking a good family
history. Other, novel risk markers for coronary disease are
also of interest, and Tseng et al. (168) examined whether
evidence of subclinical hypothyroidism was associated with
subsequent coronary disease (168). They used the national
laboratory database in Taiwan to identify individuals with
an elevated level of thyroid-stimulating hormone but a
normal circulating level of thyroxine. Compared with con-
trols, those with subclinical hypothyroidism had 1.68 times
the risk of subsequent coronary disease. The observed
associations do not prove causation, so further study of this
question is warranted.
The efficacy of statin therapy in women has been ques-
tioned, in part because relatively fewer women have been
enrolled in clinical trials of statins. Kostis et al. (169)
addressed this issue by performing a sex-specific meta-
analysis of statin trials. They found that the relative risk of
subsequent cardiovascular events was reduced to a similar
extent in women as in men (23% vs. 19% reduction, both
p 0.0001), with no evidence of an interaction of treatment
with patient sex. Mora et al. (170) examined data in the
large JUPITER (Justification for the Use of Statins in
Primary Prevention: An Intervention Trial Evaluating Ro-
suvastatin) trial to assess which on-treatment lipid param-
eters best correlated with subsequent risk of cardiovascular
disease (CVD). They found that LDL-cholesterol levels
while on statin treatment were highly significant predictors
of future risk, with no better prediction from non–HDL-
cholesterol, apolipoprotein B, or various ratios of lipid
parameters, suggesting that simply measuring on-treatment
LDL-cholesterol levels is a reasonable approach to follow.
One barrier to use of prescription medications is their
out-of-pocket cost to patients. Choudhry et al. (171) com-
pared outcomes of patients in a large self-insured company
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patients in a control company that did not. Lowering
copayments was associated with higher rates of statin use,
but also was associated with reductions in the rate of visits
to physicians and emergency departments, so there was no
increase in overall costs to the insurer. Besides cost, the
possibility of adverse effects is another barrier to wide-
spread use of statins, especially with recent data from clinical
trials showing a higher incidence of diabetes among patients
taking statins. To examine the potential risks and benefits of
statins in the general population, Wang et al. (172) used
data in the Taiwan National Health Insurance Database to
compare outcomes in patients who and did not initiate
statin therapy. Over 7 years of follow-up, statin users were
more likely to develop diabetes than nonusers (2.4% vs.
2.1%), with a hazard ratio of 1.15, which was similar to the
risk found in meta-analyses of randomized trials. Despite
the higher risk of diabetes, acute myocardial infarction and
major adverse cardiovascular events were reduced, suggest-
ing a favorable balance of risk and benefit.
Exercise has many beneficial effects in patients at risk of
coronary disease, and in those who have already developed
clinically evident disease. In the randomized UPBEAT
(Understanding the Prognostic Benefits of Exercise and
Antidepressant Therapy) trial (173), an exercise interven-
tion in patients with coronary heart disease significantly
reduced their level of depressive symptoms, on par with the
reduction achieved by taking the antidepressant drug ser-
traline. Further evidence for the beneficial effects of exercise
comes from a longitudinal study of over 3,000 healthy adults
by Lee et al. (174). They found that patients who main-
tained or improved their level of physical fitness, determined
by serial maximal treadmill tests, had a much lower risk of
developing hypertension, metabolic syndrome, and hyper-
cholesterolemia. Conversely, patients who increased their
percentage of body fat during follow-up were significantly
more likely to develop hypertension, metabolic syndrome,
and hypercholesterolemia. High levels of body fat had an
adverse effect on mortality in a series of 570 patients referred
for cardiac rehabilitation, but the poorest outcomes of all
were seen among patients who had low body fat in combi-
nation with low lean body mass—frail patients with low
muscle mass (175).
Many patients have poorly controlled blood pressure
even with several medications. Renal denervation using
catheter-based approaches has recently been developed as
an intervention for drug-resistant hypertension, but eco-
nomic implications of this approach have not been well
understood. Geisler et al. (176) used a simulation model
to project the likely outcomes of using renal denervation in
patients with clinical characteristics of the participants of
the Symplicity HTN-2 trial (Renal Denervation in Patients
With Uncontrolled Hypertension) (mean systolic pressure
of 178 mm Hg), and estimated a lifetime cost-effectiveness
ratio of $3,100 per quality-adjusted life-year. The incre-mental cost-effectiveness ratio remained favorable when
multiple parameters in the model were varied.
The NCDR of the American College of Cardiology is an
enormous voluntary database of value in delineating the
trends and quality of cardiovascular practice. However,
questions have existed regarding the quality of the data
itself. Therefore, Messenger et al. (177) described the
process by which the accuracy of the NCDR database is
validated. Data are filtered through registry-specific algo-
rithms requiring pre-determined levels of completeness and
consistency for data fields, and internal quality assurance
protocols enforce data standards. Within each registry, 300
to 625 records are audited annually in 25 randomly identi-
fied sites. These data provide considerable evidence validat-
ing the completeness and accuracy of the NCDR database.
A paper described trends in the prevalence, awareness,
management, and control of hypertension in the United
States from 1999 to 2010 (178). Data were largely derived
from NHANES (National Health and Nutrition Examina-
tion Survey). From 2009 to 2010, the prevalence of hyper-
tension was 30.5% among men and 28.5% among women,
whereas the hypertension awareness rate was 69% among
men and 80% among women. Hypertension control rate
was only 40% for men and 56% for women. Thus, from
1999 to 2010, the prevalence of hypertension remained
stable. Although hypertension awareness, management, and
control were improved, the level remained poor, and no
improvement has been reported since 2007.
The recommendations for antibiotic prophylaxis for in-
fective endocarditis have recently been changed in the
United States to markedly restrict the number of patients
who should receive this therapy. However, the potential
consequences of this change are uncertain. To provide data
regarding this issue, Duval et al. (179) studied the temporal
trends in infectious endocarditis in 3 regions in France from
1991 to 2008, during which time, a similar restriction in
antibiotic prophylaxis was implemented. The incidence of
endocarditis remained stable over this time, as generally did
the causative organisms. Thus, scaling down antibiotic
prophylaxis was not associated with an increased incidence
of oral streptococci infectious endocarditis, and these data
are encouraging as to what should be expected in the United
States. An accompanying editorial by Wang (180) points
out that the survey did identify an increased rate of
staphylococcus infections in patients without predisposing
native valve conditions, likely attributable, not only to
increased recreational drug use, but also to increasing rates
of hemodialysis and immunosuppression.
The role of pre-participation screening of elite athletes
with electrocardiography remains controversial. Taking the
major Italian study that provided data demonstrating the
efficacy of ECG screening in reducing sudden death, Halkin
et al. (181) did a cost-effectiveness analysis of such a strategy
were it to be applied in the United States. They came to the
provocative conclusion that a similar strategy would cost
approximately 10.6 million dollars per life saved. However,
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enormous cost per life saved was due in large measure to the
cost of providing the service in the United States, and that
substantial cost reductions to achieve the same purpose
could be implemented as were already present in Italy. It is
likely that this debate will go on.
Genetics and genomics. A pharmacogenomics study this
year from Cresci et al. (183) showed that African Americans
treated with a beta-blocker were at increased risk of mor-
tality when harboring a mutation in the beta-2 adrenergic
receptor (16R allele) compared with those without the
mutation. Cresci et al. followed patients at 22 hospitals on
beta-adrenergic blockade after acute coronary syndrome for
2 years. Replicating this finding and designing studies to
mechanistically test the hypothesis will be needed. These
studies add to a growing list of evidence that mutations in
the beta-adrenergic receptors are associated with altered
response to beta-blocker therapy (184).
A locus on chromosome 4q25 has been widely associated
with atrial fibrillation (185,186). Two noncoding SNPs in
the 4q25 locus, rs10033464 and rs2200733, have been
replicated in populations of European and Asian descent,
and were found to be important in studies this year to
stratify individuals responding to antiarrhythmic drug ther-
apy (187). A total of 670 individuals in the Vanderbilt Atrial
Fibrillation Registry with a common SNP on chromosome
4q25 (rs10022464) responded less favorably to antiarrhyth-
mic drug therapy (class III antiarrhythmic drugs) than
patients carrying the wild-type allele at rs10022464. This
finding illustrates how genetic testing stratifies patients.
Daubert and Pitt (188) in an accompanying editorial agree
with the authors, suggesting a randomized, double-blinded
trial is needed to fully test the role of genetic testing for this
SNP to determine whether patients will respond to antiar-
rhythmic drug therapy.
A study from Ritchie et al. (189) provides new evidence
in their familial atrial fibrillation study that the rs2200733
SNP on chromosome 4q25 acted as a “modifier” gene. In
other words, the presence of a SNP on chromosome 4q25
was helpful in determining whether a patient carrying a rare
mutation would eventually develop atrial fibrillation. A
succinct and well-written refresher by Judge (190) on the
current field of genetics and atrial fibrillation accompanies
the paper.
QT prolongation is a serious adverse event of antiar-
rhythmic drugs. A study from Jamshidi et al. (191) provided
new evidence that a SNP (rs10800397) in the gene nitric
oxide synthase 1 adaptor protein (NOS1AP) is associated
with drug-induced QT prolongation. SNPs in NOS1AP have
previously been associated with QT prolongation interval
(192–194). The antiarrhythmic drug driving the majority of
the changes in this study is amiodarone. These experiments
raise the question of genetic testing to identify patients at
increased risk of QT prolongation when they are prescribed an
antiarrhythmic drug. A limitation of this study was the smallnumber of patients treated with amiodarone that had ventric-
ular arrhythmia and QT prolongation.
Approaches designed to test the functional impact of
more than 1 DNA mutation simultaneously acting on a
single cell remain a challenge. Mann et al. (195) address this
by modeling the electrical properties of cells with 1 or more
mutations in potassium channels. Atrial fibrillation pro-
bands (n  20) and 240 controls were sequenced. Novel
variants (both nonsynonymous variants and rare variants)
were more prevalent in the cases versus controls. Modeling
studies were then completed to determine in silico the
electrical properties of these cells with 1 or more mutations.
This study identifies novel rare variants associated with
atrial fibrillation and also highlights a modeling system to
evaluate the impact of multiple variants in a single individ-
ual on action potential duration.
Of the 4 lipid categories in humans, LDL-C, HDL-C,
and triglycerides are affected by diet. However, plasma levels
of Lp(a) are thought to be mediated mainly by genetics
(196). High Lp(a) is associated with increased CVD risk.
However, the mechanisms through which high plasma
levels of Lp(a) increase risk of CVD (thrombosis or athero-
sclerotic mediated) has been controversial. Helgadottir et al
(197). tested the hypothesis that 2 variants in LPA con-
ferred susceptibility mainly to atherosclerosis or to throm-
bosis, and showed that LPA sequence variants were associ-
ated with atherosclerosis and not thrombosis. An
accompanying editorial reflects on additional genetic studies
with LPA and the current gaps in our understanding re LP(a)
biology (198).
Crotti et al. (199) provided an insightful look at genetic
testing on the 12 Brugada syndrome susceptibility genes in
the largest published cohort of unrelated patients referred
for Brugada syndrome genetic testing. The authors found
mutations in the gene SCN5A, encoding a sodium channel,
to be the most prevalent in the patients referred for Brugada
syndrome genetic testing (listed in Table 2). Additional rare
variants were also identified in SCN5A, as well as
CACNA1C and KCNE3. Genetic mutations were harbored
in 50% of males under age 20 years in this cohort, much
higher than the entire cohort. In sum, these data provide
new evidence that a positive SCN5A genetic test plus a
Brugada ECG pattern (spontaneous or drug-induced type
1) may be sufficient for a clinical diagnosis of Brugada
syndrome. The editorial from Kaufman (200) provides an
important clinical refresher on Brugada syndrome as well as
a critical summary of the article and the cohort examined.
Elevated atrial natriuretic peptide (ANP) has long been a
biomarker for increased risk of cardiovascular disease, and
increased mortality in patients with heart failure, stroke and
ischemic heart disease (201). Barbato et al. (201) provide
new evidence for an association between a SNP in ANP
(rs5065) and increased susceptibility to acute coronary
syndrome and unfavorable prognostic value in coronary
artery disease. A curious aspect of this study is that the SNP
did not correlate with plasma N-terminal pro-atrial natri-
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Our understanding of the genetic mechanisms leading to
dilated cardiomyopathy continues to evolve. Mann et al.
(202) characterized a variant R222Q in the SCN5A gene in
a large kindred with dilated cardiomyopathy, multiple
arrhythmias, and premature ventricular complexes. Carriers
of the R222Q mutation responded more favorably to
amiodarone or flecainide, drugs with sodium-channel
blocking properties, compared with standard heart failure
therapies.
A state-of-the-art tour de force review for hypertrophic
cardiomyopathy provided an up-to-date clinical and molec-
ular summary as well as a practical guide for the clinician for
determining when and how to order genetic testing for the
hypertrophic cardiomyopathy patient (203). This review
contains clear definitions in tables and practical guides to
genetic testing to aid in the clinical diagnosis of hypertro-
phic cardiomyopathy.
The paper, “Risk Factors for Malignant Ventricular
Arrhythmias in Lamin A/C Mutation Carriers” from van
Rijsingen et al. (204) identifies 4 independent risk factors to
facilitate the selection of LMNA mutation carriers most
likely to benefit from an ICD. These factors include
nonsustained VT, LVEF45% on the first clinical contact,
male, and non-missense mutations. The high rate of sudden
cardiac death and progression to heart failure is confirmed
in this study, furthering the need to better understand the
mechanisms behind laminopathies and identify more effec-
tive treatment options. Maron and Semsarian (205) accom-
pany this with an aerial view perspective on preventing
sudden cardiac death in patients with cardiomyopathies.
The adenosine triphosphate-sensitive K (KATP) chan-
nel is important metabolically in the heart for matching
high-energy phosphates/energy substrate metabolism with
cellular electrical activity. The KATP channel is composed
of different subunits (Kir6.x) that together form a central
channel pore. A major finding of a genomic study by
Raeis-Dauve et al. (206) is that expression of Kir6.2, the
potassium inward rectifier in the left ventricle, is regulated
by tissue hypoxia. An accompanying editorial by Lopaschuk
and Jaswal (207) proposes a model in which these data may
be part of a larger stress adaptation model whereby hypoxia
stimulates HIF-1alpha, leading to increased Kir6.2 expres-
sion, remodeling of the proteome/energy metabolism, and a
final adaptation to hemodynamic cardiac stress.
Identifying molecular targets to effectively treat thoracic
aortic aneurysms is an area of intense research. Das et al.
(208) provide new evidence in humans that expression of a
pro-inflammatory protein that activates the receptor for
advanced glycation end products, S100A12, in a thoracic
aneurysm is associated with increased hospital length of
stay. When S100A12 was reduced in human aortic smooth
muscles in vitro, proinflammatory and proapoptotic regula-
tory factors were attenuated. These translational studiessuggest that S100A12 may be an important target in the
field of thoracic aneurysms.
Controversies surrounding 17beta-estradiol (E2) and car-
diovascular risk continue to generate discussion. An edito-
rial from Banka (209) frames the current estrogen debate
and provides a clear perspective on the sex-specific findings
reported by Kararigas et al. (210) showing that estrogen
actions in the heart are different between men and women.
E2 treatment of male cardiac myocytes led to decreased
cardiac function mediated through the stimulation of myo-
sin regulatory light chain interacting protein leading to a
decrease in myosin regulatory light chain. E2 levels increase
in aging and obese men. How large of an impact E2 levels
have on increased risk of cardiovascular disease in aging and
obese men is not currently known.
A study by Benn et al. (211) takes a new twist on diabetes
as a risk factor for cardiovascular disease. This study showed
that SNPs that were associated with nonfasting plasma
glucose were associated with increased risk of ischemic heart
disease and myocardial infarction (211). This study provides
increasing evidence that elevated nonfasting glucose in-
creases the risk of individuals developing ischemic heart
disease and a myocardial infarction.
Screening novel DNA variants to functionally define
their role in arrhythmias, sudden cardiac death, abnormal
calcium handling, and other additional cardiovascular phe-
notypes has often been challenging. The field has begun to
explore the use of human-induced pluripotent stem cells
(iPSCs) for this purpose. Lior Gepstein’s laboratory (Itzhaki
et al. [212]) used human iPSCs from dermal fibroblasts
from a catecholaminergic polymorphic ventricular tachycar-
dia (CPVT) patient to model CPVT due to a mutation in
a cardiac ryanodine receptor. The human iPSCs were
characterized by positive staining for all 3 germ layers,
nestin (ectoderm), alpha-fetoprotein (endoderm), and
desmin (mesoderm), as well as expression of endogenous
pluripotency genes, OCT4, SOX2, NANOG, FOXD3, and
REX1. Action potential recordings and calcium handling
differed between control human iPSCs versus human iPSCs
from a patient with CPVT. An editorial from Gnecchi and
Schwartz (213) place this in context with other recently
published work.
A provocative finding from Xu et al. (214) showed that a
proapoptotic miRNA, miR-34a, is up-regulated in the bone
marrow of individuals following a myocardial infarction.
Reduction of miR-34a ex vivo in human bone marrow cells
improved the therapeutic benefit of these cells in a murine
model of myocardial infarct. These studies begin to explain
the important impact of an infarct on the profile of bone
marrow cells and how it may alter the efficacy of these cells
in healing.
A paper on platelet biology and response to antiplatelet
therapy in women provides an excellent overview of the
understudied area, including the impact of the menstrual
cycle and hormones on platelet biology. The results of most
large primary or secondary prevention trials with aspirin
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outline sex differences in bleeding associated with antiplate-
let therapies, with the majority of studies showing women to
be at increased risk. However, as pointed out, these trials/
studies are not designed to specifically address sex-specific
differences, thus additional confounding factors are likely
involved.
A state-of-the-art paper from Voora and Ginsburg (216)
reviews the “Clinical Application of Cardiovascular Phar-
macogenetics.” Cardiologists who prescribe statins, clopi-
dogrel, aspirin, warfarin, beta-blockers, or antiarrhythmic
drugs will find this paper easy to follow, timely, and succinct
in providing an update on genetic testing for patients, as
well as providing an outline of the influence of genetic
variation on patients’ response to therapy (216).
Stem cell trials for the treatment of cardiovascular disease
continue to move forward. Li et al. (217) compared different
stem cell types for paracrine potency and efficacy of myo-
cardial repair. Cardiospheres outperformed bone marrow–
derived mesenchymal stem cells, adipose-derived stem cells,
and bone marrow mononuclear cells. Given that recent stem
cell trials showed mixed results with bone marrow–derived
mesenchymal stem cells, cardiospheres may be next in line
for clinical trials.
Isolating c-kit cardiac progenitor cells from the myo-
ardium of heart failure patients, genetically engineering
hese cells to express a cardiac repair gene, and showing
mproved efficacy in a mouse model of myocardial infarction
epresent a new line of experimental approaches combining
uman progenitor cells, cardiac repair, and genetic engi-
eering (218). Pim-1 kinase, a protein that enhances cell
urvival and metabolic activity while attenuating apoptosis,
ugmented the repair potential of human progenitor cells
hen injected directly into the mouse heart concurrent with
myocardial infarction. The editorial from Bishopric (219)
f stem cell trials informs of limitations and gaps in the
eld, and the importance of this contribution from the
aboratory of Mark Sussman.
A state-of-the-art publication from Roberts and Stewart
220) describes genes and coronary artery disease. A table is
rovided that outlines risk loci for coronary artery disease/
yocardial infarction, all discovered by genome-wide asso-
iation studies (GWAS). A list of common features of
oronary artery disease genetic risk variants is also helpful
nd clear. The clinical utility of the genome-wide associa-
ion study coronary artery disease risk loci is discussed.
ongenital heart disease. A paper by Feinstein et al. (221)
resents a state-of-the-art description of current consider-
tions in the fetus with hypoplastic left heart. Included are
he prenatal diagnosis and its impact on outcomes; the
mportance of understanding the flow patterns in and the
mplications of obstructed foramen ovale and tricuspid
egurgitation as adverse fetal findings; and the impact of
etal diagnosis on prenatal recognition, allowing families to
repare for the child, receive counseling, and genetic testing.
he pre-operative stabilization of hypoplastic left heart (abies with prostaglandin E1 and strategies to seek overall
mproved cardiac output includes intubation, hypoventila-
ion with inhaled nitric oxide, and carbon dioxide to
ncrease pulmonary resistance and direct cardiac output to
he body. The important evolution of the Norwood strategy,
odified Blalock-Taussig; and then the actual Norwood
odification with a right ventricle (RV) to pulmonary artery
PA) conduit, now widely used. The Pediatric Heart Net-
ork randomized patients to Blalock shunt and to RVPA
onduit, in which the RVPA conduit was found to be
ignificantly superior. This review highlights the hybrid
nterventional catheterization combination approaches us-
ng percutaneous ductus arteriosus stenting and bilateral
ulmonary artery bands to stabilize these patients. The
aper highlights the impact of heart transplantation on this
isease and the need for diagnostic studies before the final
orthrop completion stage. Lastly, consideration shows
ontan models and the fluid dynamic circulation of wall
hear stress, and application of the latest computational
imulation tools to better understand this disease and its
utcomes.
A review by Pahl et al. (222) used the Pediatric Cardio-
yopathy Registry, which has enrolled 3,500 infants, chil-
ren, and adolescents, all under the age of 18 years with
ardiomyopathy from 100 centers, from 1990 to 1995,
ooking at the potential risk for transplantation and sudden
eath. The 5-year incidence of sudden death was 3%; the
ajor risk factors were age at diagnosis 14.3 years, LV
ilation (which most patients probably had), and LV
osterior wall thinning. Patients meeting these criteria
hould be considered for implantable cardioverter-
efibrillator device placement. Fifty-six of the 280 deaths
id not have an identifiable cause—some of these were
robably sudden deaths rather than deaths due to heart
ailure. This rate of sudden cardiac death is much lower than
hat for adults.
A study by D’Udekem et al. (223) reviews a database of
atients with univentricular heart from 1990 to 2008 at
oyal Melbourne Children’s Hospital. Among the risk
actors for poor outcome were atrioventricular valve regur-
itation, not having transposition, heterotaxy, and right
entricular dominance—which, although the outcomes of
his latter group improved over the course of the study, still
ad the largest risk. In an editorial comment, Backer (224)
eviews other reports all pointing out that right ventricular
ominance remains a major risk factor, but appears to
ecrease in risk (as does overall risk) after bilateral cavopul-
onary anastomosis.
An interesting paper from Chubb et al. (225) reviews
ong-term outcomes following catheter pulmonary valvot-
my for pulmonary atresia with intact ventricular septum.
hey had 39 patients, 37 of whom had successful valve
erforation—17 had stenting of the ducts. Eight died
ithin the first 35 days, with no deaths thereafter. No late
rrhythmias or ischemic events—87% survived; 25 patients
83% of survivors) now have a biventricular circulation. A
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duct. There was no catch-up growth in the RV in patients—
even those who had a biventricular outcome. Multiple
interventions are often required to achieve biventricular
circulation, and venting of the duct may reduce hospital stay
and repeat procedures.
Another paper presents a series of Ebstein’s patients
undergoing surgeries occurring between October 1980 and
January 2010 (226). Many of them had symptoms including
heart failure, tachyarrhythmia not amenable to therapy,
atrial septal defect progressive cardiomegaly, and other
associated problems. Pre-operative electrophysiology study
was performed, and ablation of accessory conduction path-
ways was performed if indicated; elimination of shunts,
including atrial septal defect; selective plication of the
atrialized RV; and reconstruction or replacement of aortic
valve. Of 81 patients, 65 had tricuspid valve replacements,
including mechanical Starr-Edwards, mechanical bileaflet
prostheses, and porcine valve more recently. The patients
had significant other risk factors—hyperlipidemia, diabetes
mellitus, and coronary artery disease (in 15 patients).
Seventy-eight patients survived, and 13 died during follow-
up, especially those with older age at surgery and lower
ejection fraction or history of pre-operative heart failure.
Although this surgery may be complex, operations per-
formed in an experienced center can offer a low mortality
(around 4%), and produce better results if performed earlier
in the evolution of symptomatology of these patients.
A paper by Emani et al. (227) describes patients who
were split between traditional single-ventricle palliation and
progressive LV recruitment (34 of each). The staged left
ventricular recruitment strategy includes initial palliation by
a Glenn or hemi-Fontan with resection of endocardial
fibroelastosis, treating the mitral valve with valvuloplasty,
separating fused papillary muscles, chordal elongation and
commissurotomy, as well as performing aortic valvuloplasty,
atrial septal resection, and sometimes transcatheter balloon
dilation of aortic and mitral valves. Once patients had LV
growth, the biventricular procedure included takedown of
the aortopulmonary anastomosis, and re-establishment of
adequate right and left ventricular outflow tract continuity,
sometimes by translocation of the pulmonary artery root
into the LV outflow tract and RV outflow tract conduit
reconstruction. During the 15 years of study, an increasing
number of patients have undergone prenatal LV recruit-
ment by aortic valvuloplasty, and postnatal aortic balloon
valvuloplasty. Most of the patients from the time of initial
hospitalization for surgery, catheterization, and medical
treatment had 94 in-house days, but of the 34 gradual LV
recruitment patients, 15 ended up having Fontan and left
heart rehabilitation, 12 of whom proceeded to a biventricu-
lar conversion. This is a single-center study, employing an
aggressive strategy, by a well-qualified team, resulting in
significant patient rehabilitation to a biventricular outcome
in a group that traditionally rarely goes beyond the Fontan
stage. pA paper in press by Bautista-Hernandez et al. (228)
presents a pilot experience with atrioventricular valve annu-
lar remodeling with a bioabsorbable ring for regurgitation in
6 small children. Four children had previously had AV canal
repair (2 heterotaxy, 1 Shone’s complex), 1 had a dysplastic
mitral valve, and 1 had hypoplastic left heart syndrome.
Four patients required reoperation—2 unrelated to the AV
valve (aortic valve replacement and Fontan completion). In
2 redo patients, the bioring was observed to be fully
reabsorbed and replaced with firm fibrotic tissue in the
intra-annular position, confirming the valve was growing at
a respectable rate. The conclusion of this paper was also
supported by quoting a larger experience in Europe.
General topics. Ivabradine is a chronotropic agent that
blocks the If current and slows heart rate by mechanisms
istinct from other drugs, such as beta-adrenergic receptor
r calcium channel blockers. Inappropriate sinus tachycardia
IST) is a p syndrome that causes an inappropriate increase
n sinus rhythm at rest or with exercise out of proportion to
hysiological demands, resulting in palpitations that are
ifficult to treat. In a randomized, double-blind crossover
rial, Cappato et al. (229) treated 21 subjects (average age 37
ears old) with symptomatic IST with ivabradine 5 mg
wice daily or placebo for 6 weeks. Ivabradine significantly
educed heart rates at rest, with standing, during exercise,
nd 24-h mean heart rate, and reduced symptoms by more
han 70%, including palpitations, pre-syncope, dyspnea, and
atigue. Exercise performance improved, and there were
inimal side effects from treatment. Scheinman and Ve-
antham (230) note these results provide “a ray of hope”
reating IST, a rare syndrome with disabling symptoms that
an be frustratingly difficult to control.
Blood pressure (BP) is modified with aging as arterial
tiffness increases. Benetos et al. (231) addressed the prog-
ostic value of different measures of BP and arterial stiffness
n cardiovascular risk and morbidity in the longitudinal
ulticenter PARTAGE (Predictive Values of Blood Pres-
ure and Arterial Stiffness in Institutionalized Very Aged
opulation) study. Central BP and aortic pressure wave-
orms, pulse pressure and pulse pressure amplification were
easured by carotid and femoral artery tonometry in 1,126
lderly subjects (874 women) over 80 years old. Two-year
ortality (primary endpoint) and major cardiovascular (CV)
vents were higher in patients with decreased pulse pressure
mplification, whereas neither systolic BP, diastolic BP, nor
ulse pressure were predictive. A 10% increase in pulse
ressure amplification was associated with a 24% decrease in
otal mortality and a 17% decrease in major CV events.
hese data suggest that an overly aggressive focus on
ontrolling routine BP measures may lead to iatrogenic
omplications without a beneficial reduction of CV events
r mortality.
Exposure to air pollution may have acute and long-term
ardiovascular effects. Krishnan et al. (232) examined the
ascular effects of short- and long-term exposure to fine
articulate matter 2.5 m in size (PM2.5) in a subset of
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Study of Atherosclerosis). An increase in long-term expo-
sure to fine particulate matter (PM2.5) was associated with a
ecrease in brachial artery flow-mediated dilation (FMD), a
easure of vascular endothelial function. Changes in FMD
ere independent of other traditional risk factors. These
esults indicate that long-term exposure to air pollution
lone impairs endothelial function. Brook and Rajagopalan
233) place the importance of these results in the context of
urrent levels of air pollution. The study reported a 3 g/m3
average annual increase in PM2.5 exposure caused a 0.3%
eduction in FMD. Although the reduction in FMD may
eem small, the magnitude of this effect is similar to the
dverse risk of smoking or 5 years of aging.
Perioperative statins reduce post-operative complications
f cardiac surgery, including atrial fibrillation. Antoniades et
l. (234) examined the potential mechanism for statins to
uppress oxidative stress. In 303 patients undergoing cardiac
urgery, myocardial redox state was assessed by measuring
icotinamide adenine dinucleotide phosphate (NADPH)
xidases, myocardial superoxide anion (O2
), and peroxyni-
trite (ONOO) from the right atrial appendage. An in-
crease in myocardial redox state was independently associ-
ated with increased incidence of post-operative atrial
fibrillation, inotropic support, and hospital stay. In a ran-
domized control trial with 42 statin-naive patients, treat-
ment with atorvastatin 40 mg/day compared with placebo
for 3 days before coronary artery bypass surgery decreased
NADPH oxidase activity and myocardial O2
 and
NOO. Ex vivo studies in right atrial appendage tissue
emonstrated that atorvastatin inhibited NADPH oxidase
y a Rac1-mediated mechanism. It was concluded that
re-operative statins reduce post-operative complications
rom cardiac surgery by reducing NADPH oxidases to
ecrease superoxide anion (O2
) and peroxynitrite
ONOO) production. Laufs and Adam (235) note the
apid beneficial effects of statins, which are unrelated to
holesterol lowering, represent new indications based on the
pleiotropic” effects of statins.
Angiotensin-converting enzyme inhibitors (ACEI) re-
uce cardiovascular events in patients at high risk, a mech-
nism that may involve platelets. Willoughby et al. (236)
xamined this in a randomized control trial in 119 of
atients with coronary or vascular disease and/or diabetes
nd 1 additional risk factor treated with ramipril (10 mg) or
lacebo for 12 weeks. There was no difference in platelet
ggregation, but ramipril increased platelet responsiveness
o nitric oxide (NO) in the subgroup with platelet NO
esistance at baseline and also reduced arterial stiffness and
symmetric dimethylargine (ADMA) levels, a marker of
ndothelial dysfunction. In second part of the study, these
esults were confirmed by finding that ramipril improved
latelet NO responsiveness. These finding may provide
echanistic insights as to the beneficial effects of ACEI in
igh-risk patients. Angiolillo and Capodanno (237) com-
ent that this adds to ACEI effects on vasomotor function. pThe time course and spatial distribution of inflammatory
esponses to myocardial infarction can be tracked in vivo by
dvanced imaging techniques. Lee et al. (238) used hybrid
ET and MRI to demonstrate a 5- to 6-fold increase in
acrophage/monocyte infiltration in noninfarcted remote
yocardium that peaked on day 10 in mice following
yocardial infarction. This was associated with an increase
n recruiting adhesion molecules and chemokines and ma-
rix metalloproteinase activity. Similar findings were ob-
erved in human hearts, with increased macrophage infil-
ration in the remote region following myocardial
nfarction. The recruitment of monocytes to remote zone
ay play an important role in post-MI dilation and remod-
ling. Frantz and Hofmann (239) note these results expand
ur current understanding of how different subsets of
onocytes infiltrate after myocardial infarction with proin-
ammatory effects, followed by infiltration of anti-
nflammatory monocytes that control repair processes and
ound healing. The study by Lee et al. (238) adds another
evel of complexity, by showing that anti-inflammatory
onocytes invade remote regions as well.
Phosphodiesterase-5 inhibitors (PDE5Is) decrease the
reakdown of cyclic guanosine monophosphate (cGMP) by
DE5, resulting in higher levels of nitric oxide (NO) to
nhance vasodilation (240). In small clinical trials, PDE5I
ave been effective for treating heart failure with secondary
ulmonary arterial hypertension, and is effective in prevent-
ng or treating high altitude–associated pulmonary arterial
ypertension and pulmonary edema. In pre-clinical studies,
nhibiting PDE5, which is specific for cGMP, has found
everal uses in providing cardioprotective effects in myocar-
ial infarction, doxyrubicin-related cardiomyopathy, and
uchenne muscular dystrophy (241). As the uses for
DE5Is to inhibit cGMP breakdown have expanded, other
hosphodiesterases involved in breaking down cyclic aden-
sine monophosphate (cAMP), such as PDE4, may provide
useful target. Molina et al. (242) studied PDE4, which is
xpressed in human atrial myocytes and contributes to 15%
f the total PDE activity, with PDE4D as the major
ubtype. Inhibiting PDE4 increased cAMP and L-type
alcium currents, and reduced arrhythmias induced by
eta-adrenergic receptor stimulation. PDE4 activity was
ower in right atrial tissue from patients with permanent
trial fibrillation and heart failure. It was proposed that
DE4 may represent a unique target for atrial arrhythmias.
an Wagoner and Lindsay (243) found these results were
ntriguing, as a potential additional approach managing
trial fibrillation (AF), the most common arrhythmia.
An attractive treatment strategy is to find effective drugs
hat may have beneficial off-target effects as well. Matsubara
t al. (244) examined this possibility with des-fluoro sita-
liptin (DFS), a dipeptidyl peptidase-4 inhibitor that im-
roves glucose metabolism by increasing glucagon-like pep-
ide (GLP)-1, which is used clinically to treat diabetes.
hey found that DFS decreased atherosclerosis in apolipo-
rotein-E–deficient mice fed a high-fat diet for 16 weeks,
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aortic rings. In vitro, DFS decreased inflammation in
cultured human macrophages by increasing GLP-1. In a
human study, GLP-1 levels were lower in 100 patients with
CAD compared with 100 subjects without CAD. It was
proposed that DFS, used to treat diabetes, also may have
antiatherogenic effects by inhibiting macrophages and im-
proving endothelial function.
Murohara (245) commented on the advantages of
incretin-related drugs such as DFS, which increase GLP-1
to reduce blood glucose levels without a high risk for
inducing hypoglycemia. DFS attenuated the release of
inflammatory cytokines from macrophages by a GLP-1–
mediated pathway; others have shown that GLP-1 ana-
logues can decrease macrophage infiltration to inhibit
atherosclerosis.
A review by Marzilli et al. (246) challenges conventional
wisdom about the nature of chronic ischemic coronary
disease, suggesting that inflammation and abnormalities of
the microvasculature and the myocardium play important
roles in the pathogenesis of this disease. The authors make
the case that epicardial stenoses have received excessive
attention as the cause for ischemic events and suggest that
ongoing efforts must address these other causes. This is a
radical hypothesis that may just be correct.
A study by Patel et al. (247) demonstrates that obtaining
a pre-hospital ECG by emergency responders slightly pro-
longs the time at the scene in patients with chest pain (by a
few seconds), but actually reduces the time needed to reach
the hospital in STEMI patients (by several minutes). This
study, conducted in more than 21,000 chest pain patients
makes a strong case for routine use of a pre-hospital ECG
by first responders.
A study by Hannan et al. (248) compared the appropri-
ateness of bypass surgery (CABG) and PCI in patients with
stable coronary symptoms studied through the New York
State Reporting System. More than 90% of the CABG
patients met current appropriateness guidelines, and only
1.1% were deemed inappropriate. For PCI, only 36.1% were
deemed appropriate, 14.3% were inappropriate, and 49.6%
of patients had uncertain indications for the procedure.
A paper by Tsimikas et al. (249) demonstrates that the
ratio of oxidized phospholipids/apolipoprotein B confers an
increased risk of major adverse cardiovascular outcomes
during 15 years of follow up. For the highest tertile, this
biomarker confers a hazard ratio of 2.4 for CVD and 3.6 for
stroke. These data demonstrate the pathophysiological im-
portance of oxidized lipids and suggest that the ratio might
be useful in reclassifying individuals into higher- or lower-
risk categories.
Valvular heart disease. Recently a new syndrome of AS
characterized by severe obstruction with a low gradient and
a low-flow state despite preserved left ventricular ejection
fraction has been recognized. Clavelet al. (250) studied the
outcome of 187 such patients matched with a similar
number of patients with either moderate or severe AS witha high gradient. They observed that the prognosis of the
patients with paradoxical low-flow, low-gradient severe AS
was worse than those with either of the other 2 presenta-
tions, emphasizing the importance of properly identifying
this cohort of patients. In an accompanying editorial,
Baumgartner (251) points out that low-flow, low-gradient
aortic stenosis remains a paradoxical and challenging con-
dition, but that mounting evidence supports its existence
and the need to treat it aggressively.
Two Journal papers dealt with conditions associated with
AS. Capoulade et al. (252) reported on the impact of
metabolic syndrome on the progression of AS. In 243
patients, metabolic syndrome accelerated the progression of
obstruction, a phenomenon most significant in younger
individuals and patients receiving statin therapy. These
findings highlight the importance of treating metabolic
syndrome in AS patients. Aksoy et al. (253) studied whether
bisphosphonates, drugs that have been shown to inhibit
vascular calcification, slow the progression of AS. They
examined 800 women followed for an average of 5 years,
using echocardiography. Patients taking biphosphonates did
not exhibit any difference in the rate of change of aortic
valve area or gradient or survival or freedom from aortic
valve replacement compared with those not taking the
agent.
Lancellotti et al. (254) examined the clinical outcomes in
patients with asymptomatic severe AS classified by trans-
valvular flow rates and pressure gradients. They observed
that patients with low-flow states had impaired prognosis,
independent of the gradient. The greatest hazard ratio
(5.26) existed for low-flow, low-gradient aortic stenosis. In
an accompanying editorial, Flachskampf and Kavianipour
(255) point out that low stroke volume is an adverse
prognostic sign in aortic stenosis, and also that this study
confirms the low incidence in sudden death in these
patients. In the same vein, a study by Henkel et al. (256)
examined the fate of patients with severe AS and asymp-
tomatic left ventricular systolic dysfunction. They found
that this condition was extremely rare, amounting to just
0.4%, but that patients with this condition did not do well
with either medical or surgical therapy.
Regarding the therapy of bioprosthetic valves, Brennan et
al. (257) studied whether anticoagulation in the first 3
months following bioprosthetic aortic valve implantation
was of value. They compared therapy with aspirin only,
warfarin only, or a combination of agents in 25,656 patients.
The most important finding of their study was that death
and embolic events were extremely rare in the first 3 months
following bioprosthetic aortic valve replacement. Although
the combination of warfarin plus aspirin was associated with
reduced risk of death and embolic events, it was associated
with an increased risk of bleeding. In an accompanying
editorial, Whitlock and Eikelboom (258) point out that the
antithrombotic treatment after bioprosthetic aortic valve
replacement is uncertain, that these data show that the
incidence of adverse events are very low and that warfarin
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combination of warfarin and aspirin be used primarily in
those patients at highest risk of thromboembolic events. In
another article, Whitlow et al. (259) reported the 12-month
results of catheter-based mitral valve leaflet repair with
MitraClip (Abbott Vascular, Santa Clara, California) from
the EVEREST II trial (Endovascular Valve Edge-to-Edge
Repair) high-risk study. The MitraClip device reduced
mitral regurgitation in the majority of patients deemed at
high risk of surgery, resulting in improved clinical symp-
toms and significant left ventricular reverse remodeling over
12 months. In an accompanying editorial, Turi and Rosen-
bloom (260) caution that the results of this trial cannot be
extrapolated readily to routine use of MitraClip for high-
risk patients. However, given the fact that patients exist
with severe mitral regurgitation and no other alternative,
they recommend that it be made available.
Whether pregnancy influences the durability of human
aortic valve substitutes was evaluated from a retrospective
registry; in 31 patients with 55 pregnancies, it was shown
that the durability of homograft (n  13) or autograft (n 
8) prostheses was not affected by pregnancy (261).
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